<SEC-DOCUMENT>0000950123-21-012961.txt : 20211026
<SEC-HEADER>0000950123-21-012961.hdr.sgml : 20211026
<ACCEPTANCE-DATETIME>20211007213409
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-21-012961
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20211008
<PUBLIC-REL-DATE>20211026
DATE AS OF CHANGE:		20211007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			4D Molecular Therapeutics Inc.
		CENTRAL INDEX KEY:			0001650648
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				473506994
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-05573
		FILM NUMBER:		211313705

	BUSINESS ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5105052680

	MAIL ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	4D Molecular Therapeutics Inc
		DATE OF NAME CHANGE:	20150811
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on October&nbsp;7, 2021.
</B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE SECURITIES ACT OF 1933 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Exact name of
Registrant as specified in its charter) </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">47-3506994</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">incorporation&nbsp;or&nbsp;organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Primary&nbsp;Standard&nbsp;Industrial</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">Classification&nbsp;Code&nbsp;Number)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(I.R.S.&nbsp;Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">Identification&nbsp;Number)</P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>5858 Horton Street #455 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Emeryville, California 94608 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(510) <FONT
STYLE="white-space:nowrap">505-2680</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal
executive offices) </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>David Kirn, M.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chief Executive Officer
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>5858 Horton Street #455 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Emeryville,
California 94608 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(510) <FONT STYLE="white-space:nowrap">505-2680</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Copies to: </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Mark V. Roeder </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Phillip S. Stoup</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Latham&nbsp;&amp;
Watkins&nbsp;LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>140 Scott Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Menlo
Park, California 94025</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Telephone: <FONT STYLE="white-space:nowrap">(650)&nbsp;328-4600</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>August J. Moretti</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chief Financial Officer</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular
Therapeutics, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>5858 Horton Street #455</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Emeryville, California 94608</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Telephone: (510) <FONT
STYLE="white-space:nowrap">505-2680</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Dave Peinsipp</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Charles S. Kim</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Kristin VanderPas</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>3 Embarcadero Center, 20th
Floor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>San Francisco, California 94111</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Telephone: (415) <FONT STYLE="white-space:nowrap">693-2000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities
Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this Form is filed to register
additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to
Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to
Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Emerging&nbsp;growth&nbsp;company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title Of Each Class Of Securities To Be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proposed<BR>Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Aggregate<BR>Offering&nbsp;Price<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount Of<BR>Registration Fee</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common stock, par value $0.0001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes the aggregate offering price of additional shares that the underwriters have the option to purchase.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:5%; font-size:8pt; font-family:ARIAL"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be
necessary to delay its effective date until the Registrant shall file&nbsp;a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of
1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#cc062a">The information contained in this preliminary prospectus is not complete and may be
changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy
these securities in any jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#cc062a">Subject to Completion, Dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021
</FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g162874g92m89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are offering
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our common stock
is listed on the Nasdaq Global Select Market under the symbol &#147;FDMT.&#148; On&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, the last reported sale price of our common stock on the Nasdaq
Global Select Market was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an
&#147;emerging growth company&#148; as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements in this prospectus and may elect to do so in future filings. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>See the section titled &#147;<A HREF="#toc162874_3">Risk Factors</A>&#148; beginning on page&nbsp;[12] to read about factors you should consider
before deciding to invest in shares of our common stock. </I></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Per&nbsp;Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to 4D Molecular Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">See the section titled &#147;Underwriting&#148; for a description of the compensation payable to the underwriters.
</P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that the underwriters sell more than
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, the underwriters have an option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us at the public offering price, less the underwriting discounts and commissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the shares against payment in New York, New York on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC &nbsp;&nbsp;</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><A NAME="toc"></A>TABLE OF CONTENTS </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_5">Industry and Market Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_16">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_17">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_18">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_19">Material U.S. Federal Income Tax Consequences to <FONT STYLE="white-space:nowrap">Non-U.S.
</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_23">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#toc162874_24">Incorporation of Certain Information by Reference </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and the underwriters have not authorized anyone to provide you any information other than that contained in this prospectus or in any free writing
prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making
an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover page of this prospectus. Our
business, financial condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For investors outside of the United States: we
have not and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the
United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">4D Molecular Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, Therapeutic Vector Evolution<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, and our logo are some of our trademarks and tradenames used in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property of other
organizations. Solely for convenience, our trademarks and tradenames referred to in this prospectus may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>
symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in
making your investment decision. Before deciding to invest in our common stock, you should read this entire prospectus carefully, including the information in our filings with the Securities and Exchange Commission (SEC), incorporated by reference
in this prospectus. Investors should carefully consider the information set forth under the title &#147;Risk Factors&#148; beginning on page&nbsp;[13] of this prospectus and those identified in our Annual Report on Form 10-K for the year ended
December&nbsp;31, 2020 and our Quarterly Report on Form 10-Q for the quarter ended June&nbsp;30, 2021. Unless the context otherwise requires or as otherwise noted, references in this prospectus to the &#147;company,&#148; &#147;4D&nbsp;Molecular
Therapeutics&#148; &#147;4DMT,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to 4D&nbsp;Molecular Therapeutics, Inc. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D
Molecular Therapeutics, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a
clinical-stage gene therapy company pioneering the development of product candidates using our targeted and evolved AAV vectors. We seek to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution, which combines
the power of directed evolution with our approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. Our targeted and evolved vectors are invented with the goals of being delivered
through clinically routine, well-tolerated and minimally invasive routes of administration, of transducing diseased cells in target tissues efficiently, of having reduced immunogenicity and, where relevant, of having resistance to <FONT
STYLE="white-space:nowrap">pre-existing</FONT> antibodies. We believe these key features will help us to potentially create targeted gene therapy product candidates with improved therapeutic profiles, and to address a broad range of diseases from
rare to large patient populations, including those that other gene therapies are unable to address. Each of our product candidates is created with one of our targeted and evolved AAV vectors. Our platform is designed to be modular, in that an
evolved vector invented for a given set of diseases can be equipped with different transgene payloads to treat other diseases affecting the same tissue types. We believe this modularity will help inform the clinical development of subsequent product
candidates using the same vector. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have built a deep portfolio of gene therapy product candidates initially focused in three therapeutic areas:
ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). We have three product candidates that are in clinical trials: <FONT STYLE="white-space:nowrap">4D-125</FONT> for the treatment of <FONT
STYLE="white-space:nowrap">X-linked</FONT> retinitis pigmentosa (XLRP), in a Phase&nbsp;1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase&nbsp;1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase&nbsp;1/2
clinical trial. In addition, INDs have been cleared by the U.S. Food and Drug Administration (FDA) for both <FONT STYLE="white-space:nowrap">4D-150</FONT> for the treatment of wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular
degeneration (wet AMD) and <FONT STYLE="white-space:nowrap">4D-710</FONT> for the treatment of cystic fibrosis lung disease. We expect to initiate clinical trial sites for both of these programs before year-end. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe our competitive advantages, combined with our highly experienced team, help to position our company to create, develop, manufacture and, if
approved, effectively commercialize targeted gene therapies that could transform the lives of patients suffering from debilitating diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Therapeutic
Vector Evolution Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Gene therapy holds tremendous promise as a transformative therapeutic class. However, the majority of gene therapies
have encountered limitations such as inflammation and toxicity, high dose </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
requirements, limited efficacy and neutralization by <FONT STYLE="white-space:nowrap">pre-existing</FONT> antibodies, due in part to their utilization of conventional AAV vectors that are
naturally occurring and <FONT STYLE="white-space:nowrap">non-targeted.</FONT> Through our Therapeutic Vector Evolution platform, we apply the principles of directed evolution to invent targeted and evolved vectors for the delivery of genes to
specific tissue types that are affected by the diseases that we are addressing. Our product candidates are designed and engineered to utilize our targeted and evolved vectors to potentially address the limitations encountered with gene therapies
utilizing conventional AAV vectors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Leveraging a wide range of molecular biology techniques, we have developed a collection of 40 distinct
libraries that are comprised of approximately one billion synthetic capsid sequences. We next define a Target Vector Profile that identifies the optimal vector features for the specific tissue type(s) and related set of diseases we seek to target,
with the goal of overcoming limitations encountered by conventional AAVs. We then deploy Therapeutic Vector Evolution with our capsid libraries in <FONT STYLE="white-space:nowrap">non-human</FONT> primates (NHPs) and use competitive selection to
identify targeted and evolved vectors from our libraries that demonstrate the strongest match to the Target Vector Profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on preclinical
data reported to date from our NHP and human cell models, including preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> comparisons with relevant conventional AAV vectors, we have observed that
our targeted and evolved vectors were well-tolerated and achieved enhanced delivery, increased transgene expression, reduced immunogenicity and/or improved antibody resistance when compared to conventional AAV vectors. We have not compared our
targeted and evolved vectors to conventional AAV vectors in patients in clinical studies. As we advance through clinical trials, we plan to evaluate the following potential design features of our targeted and evolved vectors and product candidates:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Tolerability</U>:<B> </B>&nbsp;&nbsp;&nbsp;&nbsp;Well-tolerated therapies with a low inflammation profile, low dose
requirements and routine, safe routes of delivery </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Biologic activity</U>:<B> </B>&nbsp;&nbsp;&nbsp;&nbsp;Effective delivery to targeted tissues, efficient transgene
expression in targeted tissues, and/or resistance to neutralization by <FONT STYLE="white-space:nowrap">pre-existing</FONT> antibodies </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Routine routes of administration</U>:<B> </B>&nbsp;&nbsp;&nbsp;&nbsp;Routine, well-tolerated and minimally invasive
routes of administration, including intravitreal, aerosol and intravenous delivery </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><U>Antibody resistance</U>:<B> </B>&nbsp;&nbsp;&nbsp;&nbsp;Resistance to neutralization by
<FONT STYLE="white-space:nowrap">pre-existing</FONT> antibodies, translating into improved efficacy, larger addressable patient populations, and the potential for <FONT STYLE="white-space:nowrap">re-dosing</FONT> </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Candidate Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing a diverse pipeline of product candidates for both rare and large market diseases, including patient populations that other gene
therapies are unable to address. Our initial product candidates are focused on the following therapeutic areas: ophthalmology, cardiology and pulmonology. Each of our product candidates leverages a targeted and evolved vector we invented through our
Therapeutic Vector Evolution platform. Below is a summary of our product candidate pipeline and our next anticipated milestones: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g162874g44t14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><I>Abbreviations: CHM, choroideremia; DR/DME, diabetic retinopathy, diabetic macular edema; IND, investigational new
drug; IV, intravenous; Wet AMD, wet age-related macular degeneration; XLRP, x-linked retinitis pigmentosa. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Our Ophthalmology Programs: Intravitreal Product
Candidates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are developing product candidates to treat tissues throughout the retina. Our targeted and evolved AAV vector, R100, was invented
for routine intravitreal injection, leading to transgene expression across the entire surface area of the retina, and in the major cell layers of the retina. We currently have four wholly-owned ophthalmology product candidates that utilize our
proprietary intravitreal R100 vector: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">4D-125</FONT></U>:
<FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;4D-125</FONT> is in an ongoing Phase 1/2 clinical trial in patients with XLRP due to mutations in the <I>RPGR</I> gene. XLRP is a rare inherited
<FONT STYLE="white-space:nowrap">X-linked</FONT> recessive genetic disorder that causes progressive vision loss and blindness in boys and young men. There are currently no approved therapies for XLRP. The estimated prevalence of XLRP due to
<I>RPGR</I> variants is approximately 24,000 patients in the United States, and France, Germany, Italy, Spain and the United Kingdom <FONT STYLE="white-space:nowrap">(EU-5).</FONT> We expect to enroll patients with a broad range of disease severity,
including those earlier in the progression of their disease. We expect to report initial clinical data from this trial in October 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><U>4D-150</U>: &nbsp;&nbsp;&nbsp;&nbsp;4D-150 is in clinical development for wet AMD, a large market ophthalmology
indication. There are on average 200,000 new incidences of wet AMD per year in the United States alone. The FDA has cleared the IND for this program. The active IND enables the initiation of 4D-150 Phase 1/2 clinical trial sites, which is expected
before year-end. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">4D-110</FONT></U>:
<FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;4D-110</FONT> is in an ongoing Phase 1 clinical trial in patients with choroideremia. Choroideremia is a monogenic blinding disease, affecting approximately 13,000 patients in the United
States and <FONT STYLE="white-space:nowrap">EU-5.</FONT> We expect to enroll patients with a broad range of disease </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
severity, including those earlier in the progression of their disease. On September 16, 2021, the license agreement with Roche was terminated, and we regained full rights to 4D-110. We expect to
report updated interim clinical data from this trial in 2022. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">4D-135</FONT></U>:
<FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;4D-135</FONT> is in preclinical development for autosomal dominant retinitis pigmentosa (adRP) due to mutations in the <I>RHO</I> gene. The prevalence in the United States and EU-5 is
estimated to be approximately 11,600. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Cardiology Pipeline: Intravenous Product Candidates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">With our cardiology product candidates, all of which are wholly owned, we plan to treat patient populations in both primary cardiomyopathies, that
involve the heart only, as well as cardiomyopathies that are secondary to systemic diseases, such as lysosomal storage diseases. Our cardiology product candidates utilize our targeted and evolved AAV vector, C102, which was invented for routine low
dose intravenous administration and delivery to the heart, leading to transgene expression in heart muscle cells throughout the organ. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our initial
cardiology product candidate, <FONT STYLE="white-space:nowrap">4D-310,</FONT> is in an ongoing Phase 1/2 clinical trial in adult patients with classic (severe) Fabry disease. We estimate the potential initial addressable male Fabry patient
population in the United States and <FONT STYLE="white-space:nowrap">EU-5</FONT> to be up to 19,000 individuals, approximately 57% of whom suffer from classic Fabry disease. <FONT STYLE="white-space:nowrap">4D-310</FONT> is designed to address all
critically affected organs, including the heart, kidney and blood vessels through direct intracellular transgene expression. To our knowledge, <FONT STYLE="white-space:nowrap">4D-310</FONT> is the only Fabry product candidate specifically designed
to treat cardiomyocytes. We expect to report initial clinical data with respect to three patients in this trial in October 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pulmonology Pipeline: Aerosol
Delivery Product Candidates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">With our pulmonology product candidates, all of which are wholly owned, we plan to treat diseases that affect the
lungs. Our pulmonology product candidates utilize our targeted and evolved vector, A101, which was invented for aerosol delivery to all major regions within the lung, including airways and alveoli, and successful penetration of the mucus barrier for
transduction of lung airway cells, overcoming potential barriers such as <FONT STYLE="white-space:nowrap">pre-existing</FONT> AAV antibodies and other inhibitory proteins within the mucus barrier. Our products utilizing A101 are designed for
delivery as an aerosol to the lung epithelial cell surface resulting in efficient airway and alveolar cell transduction and transgene expression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our initial pulmonology product candidate, <FONT STYLE="white-space:nowrap">4D-710,</FONT> is in clinical development for cystic fibrosis lung disease.
According to the Cystic Fibrosis Foundation, more than 30,000 people in the United States and more than 70,000 people worldwide are living with cystic fibrosis. The FDA has cleared the IND for this program. The active IND enables the initiation of <FONT
STYLE="white-space:nowrap">4D-710</FONT> Phase 1/2 clinical trial sites, which is expected before <FONT STYLE="white-space:nowrap">year-end.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have designed and are continually
developing and scaling a robust <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing platform for both GMP and <FONT STYLE="white-space:nowrap">non-GMP</FONT> manufacturing. Our current <FONT STYLE="white-space:nowrap">in-house</FONT>
manufacturing capabilities include GMP manufacturing, production capabilities for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> GLP toxicology studies and research candidate production. Our team has manufactured over 140 total lots of AAV
vectors for research or clinical use. We have <FONT STYLE="white-space:nowrap">in-house</FONT> cGMP manufacturing capabilities for clinical trial material production. Our manufacturing team has completed and released multiple lots of clinical trial
material for our three product candidates in clinical development. Our manufacturing facilities are on-site at our </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
headquarters in Emeryville, California and include process development labs, an analytical development lab and a 3,200 square feet cGMP manufacturing facility. In addition, the Company recently
initiated the expansion of cGMP compliant manufacturing facilities and analytical laboratories at 4DMT headquarters in Emeryville, CA to support manufacturing and analytical testing of current and future product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our experienced team consists of biotherapeutics
developers, entrepreneurs, innovative gene therapy scientists and clinicians to execute our platform, product design and development and commercialization strategies. Collectively, our team has more than 100 years of combined experience in the field
of viral vector gene therapy, including leadership of over 30 clinical trials from Phase 1 through Phase 3 and product approval. We are led by our Chief Executive Officer and <FONT STYLE="white-space:nowrap">co-founder,</FONT> David Kirn, M.D., who
has over 25 years of experience creating and growing therapeutic platform companies. Our Executive Chairman, John Milligan, Ph.D., is the former CEO and President of Gilead Sciences. Our Chief Scientific Advisor and
<FONT STYLE="white-space:nowrap">co-founder,</FONT> David Schaffer, Ph.D., pioneered the application of directed evolution to the capsid of AAV vectors 20 years ago. Our Chief Operating Officer and Chief Technical Officer, Fred Kamal, Ph.D., has
over 25 years of industry experience in product manufacturing and quality, including most recently with AveXis, Inc. where he was a key contributor to the development and biologics license application (BLA) for the AAV product Zolgensma. Our Chief
Medical Officer, Robert S. Fishman, M.D., brings over 20 years of clinical trial execution and product development expertise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our vision is to unlock the full potential of gene therapy to address as many patient populations as possible in both rare and large market diseases. We
have developed the following strategies and guiding principles to achieve our goals: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Invent targeted and evolved AAV vectors using the power of directed evolution to unlock the full potential of gene therapy
with transformative gene therapy products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Apply our modular product design to help inform the clinical development of subsequent product candidates using the same
vectors used for prior product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Develop and commercialize a diverse portfolio of transformative gene therapy products in a broad range of therapeutic areas
with significant unmet needs, including rare and large patient populations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Build a fully integrated biopharmaceutical company by advancing our capabilities in product development and
commercialization, and by expanding our manufacturing facilities and internal proprietary Good Manufacturing Practice (GMP) capabilities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Selectively execute strategic collaborations to maximize the potential value of our Therapeutic Vector Evolution platform.
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks
are described more fully in the section titled &#147;Risk Factors&#148; immediately following this prospectus summary and in our Annual Report on Form 10-K for the year ended December 31, 2020 and our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2021, which are incorporated by reference herein. These risks include the following, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are in the early stages of drug development and have a very limited operating history and no products approved for
commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have had recurring net losses, and we expect to continue to incur significant net losses for the foreseeable future.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Even if this offering is successful, we will require substantial additional capital to finance our operations. If we fail
or are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">All of our product candidates are based on a novel AAV gene therapy technology with which there is limited regulatory and
clinical experience to date, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. Further, the regulatory approval process for novel product candidates such as ours
can be more expensive and take longer than for other, better known or extensively studied therapeutic modalities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Gene therapies are novel, complex and difficult to manufacture. We could experience production problems that result in
delays in our development or commercialization programs, limit the supply of our products or otherwise seriously harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Adverse public perception or regulatory scrutiny of gene therapy technology may negatively impact the developmental
progress or commercial success of products that we develop alone or with collaborators. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates,
which would prevent, delay or limit the scope of regulatory approval and commercialization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, expensive,
time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our employees, independent contractors, consultants, research or commercial partners or collaborators and vendors may
engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses
granted to us by others, and the patent protection, prosecution and enforcement for some of our product candidates may be dependent on our licensors. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We were formed on September&nbsp;12, 2013 as a Delaware limited liability corporation under the name 4D Molecular Therapeutics, LLC. On March&nbsp;11,
2015, 4D Molecular Therapeutics, Inc. was incorporated as a Delaware corporation. On March&nbsp;20, 2015, 4D Molecular Therapeutics, LLC merged with 4D Molecular Therapeutics, Inc., with 4D Molecular Therapeutics, Inc. being the surviving entity.
Our principal executive offices are located at 5858 Horton Street #455, Emeryville, California 94608, and our telephone number is <FONT STYLE="white-space:nowrap">(510)&nbsp;505-2680.</FONT> Our website address is www.4dmoleculartherapeutics.com.
The information on, or that can be accessed through, our website is not part of this prospectus. We have included our website address as an inactive textual reference only. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). We will remain an emerging growth company
until the earlier of (i)&nbsp;December 31, 2025, (ii)&nbsp;the last day of the year in which we have total annual gross revenue of at least $1.07&nbsp;billion, (iii)&nbsp;the last day of the year in which we are deemed to be a &#147;large
accelerated filer&#148; as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> under the Securities Exchange Act of 1934, as amended (the Exchange Act), which would occur if the market value of our common stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such year or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements
that are otherwise generally applicable to public companies. As an emerging growth company: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will present only two years of audited financial statements, plus unaudited financial statements for any interim period,
and related management&#146;s discussion and analysis of financial condition and results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the
assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will provide less extensive disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will not require stockholder <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive
compensation or golden parachute arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will take advantage of extended transition periods to comply with new or revised accounting standards, delaying the
adoption of these accounting standards until they would apply to private companies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also a &#147;smaller reporting
company&#148; as defined in the Securities and Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller
reporting companies and will be able to take advantage of these scaled disclosures for so long as the market value of our voting and non-voting common stock held by non-affiliates is less than $250.0&nbsp;million measured on the last business day of
our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our voting and non-voting common stock held by non-affiliates is less than $700.0&nbsp;million
measured on the last business day of our second fiscal quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As a result, the information in this prospectus and that we provide to our
investors in the future may be different than what you might receive from other public reporting companies. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_2"></A>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Underwriters&#146; option to purchase additional shares </P></TD>
<TD>We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be immediately outstanding after the offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise
their option to purchase additional shares in full). </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares in full, assuming a public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="52%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund the ongoing and planned clinical and preclinical development of our product candidates, the
further development and expansion of our pipeline, the continued expansion of our manufacturing capabilities and facilities and the remainder for working capital and other general corporate purposes. See the section titled &#147;Use of
Proceeds&#148; for a more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>See the section titled &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Nasdaq Global Select Market trading symbol </P></TD>
<TD>&#147;FDMT.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on
26,891,857&nbsp;shares of our common stock outstanding as of June&nbsp;30, 2021, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">4,238,519&nbsp;shares of our common stock issuable upon the exercise of stock options to purchase common stock that were
outstanding as of June 30, 2021, with a weighted-average exercise price of $18.84 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">98,669&nbsp;shares of our common stock issuable upon the exercise of outstanding warrants, with a weighted-average exercise
price of $6.76 per share; </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">183,600&nbsp;shares of our common stock issuable upon the exercise of stock options to purchase common stock that were
granted after June 30, 2021, each with an exercise price of $28.55 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,726,365&nbsp;shares of our common stock reserved for issuance pursuant to future awards under our 2020 Equity Incentive
Award Plan (the 2020 Plan), as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">519,156&nbsp;shares of our common stock reserved for issuance pursuant to future awards under our 2020 Employee Stock
Purchase Plan (the ESPP), as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, unless we specifically state otherwise, all information in this prospectus reflects and assumes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise of outstanding stock options or warrants described above; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise of the underwriters&#146; option to purchase additional shares. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Summary Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following tables summarize our financial data for the periods and as of the dates indicated. We derived the summary statements of operations and
comprehensive loss data for the years ended December&nbsp;31, 2019 and 2020 from our audited financial statements included in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2020, which are incorporated by reference herein.
We derived the summary statements of operations and comprehensive loss data for the six months ended June&nbsp;30, 2021 and 2020 and the summary balance sheet data as of June&nbsp;30, 2021 from our unaudited interim financial statements included in
our Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2021, which are incorporated by reference herein. Our unaudited interim financial statements are prepared in accordance with U.S. generally accepted accounting principles
(GAAP) on the same basis as our audited financial statements and include, in the opinion of management, all adjustments, consisting of normal recurring adjustments, that are necessary for the fair statement of the financial information set forth in
those financial statements. Our historical results are not necessarily indicative of the results that may be expected in the future, and our interim results should not necessarily be considered indicative of results that may be expected for the full
year or any other period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read this data together with our financial statements and related notes included elsewhere in this prospectus
and the information under the sections titled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except share and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Statements of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Collaboration and license revenue, related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Acquired in-process research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,426</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,995</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(49,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted-average shares outstanding used in computing net loss per share attributable to common
stockholders, basic and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,715,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,183,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,142,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,430,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(159,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The as adjusted column in the balance sheet data table above gives effect to the sale and issuance of shares of our common
stock in this offering, assuming a public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this
prospectus, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Each $1.00 increase or decrease in the assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, each of
the amount of our cash and cash equivalents, working capital, total assets and total stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discount and commissions and estimated offering expenses payable by us. We may also increase or decrease the
number of shares we are offering. Each increase or decrease of 1.0&nbsp;million in the number of shares we are offering would increase or decrease, as applicable, each of the amount of our cash and cash equivalents, working capital, total assets and
total stockholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed public offering price per share, as set forth on the cover page of this
prospectus, remains the same, and after deducting the underwriting discount and commissions and estimated offering expenses payable by us. The as adjusted information is illustrative only and we will adjust this information based on the actual
public offering price and other terms of this offering determined at pricing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. See our financial statements and related notes
incorporated by reference herein for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other
information in this prospectus, including our financial statements and the related notes and the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; contained in
our Annual Report on Form 10-K for the year ended December 31, 2020 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, each incorporated by reference herein, before deciding whether to invest in our common stock. If any of
the following risks actually occurs, our business, reputation, financial condition, results of operations, revenue and future prospects could be seriously harmed. The risks and uncertainties described below are not the only ones we face. Additional
risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. Unless otherwise indicated, references to our business being seriously harmed in
these risk factors and elsewhere will include harm to our business, reputation, financial condition, results of operations, future prospects and stock price. In that event, the market price of our common stock could decline, and you could lose part
or all of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to This Offering and Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares in this offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Some of the factors that may cause the market price of our common stock to fluctuate include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">results from, and any delays in, our clinical trials for our clinical-stage product candidates or any other future clinical
development programs, including any delays related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success of existing or new competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">commencement or termination of collaborations for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure or discontinuation of any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure to develop our Therapeutic Vector Evolution platform technology; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or
announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the commencement of litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the level of expenses related to any of the research programs or product candidates that we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the results of our efforts to develop additional product candidates or products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">sales of our common stock by us, our insiders, or other stockholders; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expiration of market standoff or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general economic, industry, and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant
price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Further, the stock market in general has been
highly volatile due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and political uncertainty in the United States. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our
actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. Following periods of such volatility in the market price of a company&#146;s securities, securities
class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and
divert management&#146;s attention and resources from our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If securities analysts do not publish research or reports about our business or if they
publish negative evaluations of our stock, the price of our stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The trading market for our common stock will rely in part
on the research and reports that industry or financial analysts publish about us or our business. We currently have research coverage by three financial analysts. If one or more of these analysts should drop research coverage of us or if one or more
of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn
could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>A significant portion of our total outstanding shares is restricted from immediate resale but may be sold into the
market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, upon the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements (described below), the early release of the lock-ups or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares, could reduce the market
price of our common stock. After this offering, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding based on 26,891,857&nbsp;shares of our common stock
outstanding as of June 30, 2021. Of these shares, the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares we are selling in this offering may be resold in the public market immediately, unless
purchased by our affiliates. The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares, or &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares after this offering, are currently prohibited
or otherwise restricted under securities laws, or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our stockholders with the underwriters. However, subject to applicable securities law restrictions and excluding shares of
restricted stock that will remain unvested, prohibitions and restrictions on the&nbsp;sale of these shares in the public market will be lifted beginning &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;days after the date of this prospectus. Goldman Sachs&nbsp;&amp;
Co. LLC may, in its sole discretion, release all or some portion of the shares subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time and for any reason. Shares issued upon the exercise
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
of stock options outstanding under our equity incentive plans, or pursuant to future awards granted under those plans, will become available for sale in the public market to the extent permitted
by the provisions of applicable vesting schedules, any applicable market standoff and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, and Rule&nbsp;144 and Rule&nbsp;701 under the Securities Act of 1933, as amended (the Securities Act).
See the section of this prospectus titled &#147;Shares Eligible for Future Sale&#148; for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Moreover, after this offering,
holders of an aggregate of 11.6&nbsp;million shares of our common stock will have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may
file for ourselves or other stockholders. We also plan to register all shares of our common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance and
once vested, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the section of this prospectus titled &#147;Underwriters.&#148; If any of these additional shares are
sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Raising additional capital may
cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will seek additional capital through one or a combination of public and private equity offerings, debt financings, strategic partnerships and
alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions
and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional capital through the sale of equity securities, your ownership interest will be diluted,
and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as
limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally,
any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing
arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Insiders will continue to have substantial influence over us after this offering, which could limit your ability to affect the outcome of key transactions,
including a change of control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After this offering, our directors, executive officers, holders of more than 5% of our outstanding stock and
their respective affiliates will beneficially own shares representing approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and
affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our
company and might affect the market price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; and as a result of the
reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404, reduced disclosure
obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments
not previously approved. In addition, as an &#147;emerging growth company&#148; the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to
private companies. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for
new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common
stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We
will remain an emerging growth company until the earlier of (1)&nbsp;December&nbsp;31, 2025, (2)&nbsp;the last day of the year in which we have total annual gross revenue of at least $1.07&nbsp;billion, (3)&nbsp;the last day of the year in which we
are deemed to be a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which would occur if the market value of our common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such year or (4)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even after we no longer qualify as an
&#147;emerging growth company,&#148; we may still qualify as a &#147;smaller reporting company,&#148; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including, among other things, not
being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, presenting only the two most recent fiscal years of audited financial statements in our Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have and will incur significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance
initiatives. We may fail to comply with the rules that apply to public companies, including Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would seriously harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have and will incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting
obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Market and the rules of the Securities and Exchange Commission (SEC) require that we satisfy certain corporate
governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules
and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as
a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to
attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#146; and officers&#146; insurance, on acceptable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to Section&nbsp;404 of The Sarbanes-Oxley Act of 2002 (Section&nbsp;404) and the related rules of the SEC, which generally require our
management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Beginning with the second annual report that we will be required to file with the SEC, Section&nbsp;404
requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain
exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404.
Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the
effectiveness of our internal controls over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To date, we have never conducted a review of our internal control for the purpose
of providing the reports required by these rules. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in
our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing
basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition,
as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we depend in
part on CROs to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Market or other
adverse consequences that would seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Purchasers in this offering will experience immediate and substantial dilution in the book value
of their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The public offering price of our common stock is substantially higher than the pro forma net tangible book value per
share of our common stock before giving effect to this offering. Accordingly, if you purchase our common stock in this offering, you will incur immediate substantial dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, based on an assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, and our pro forma net tangible book value as of
June 30, 2021. In addition, following this offering, purchasers in this offering will have contributed approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the total gross consideration paid by stockholders to us to purchase shares of our common stock,
through June&nbsp;30, 2021, but will own only approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the shares of our common stock outstanding immediately after this offering. Furthermore, if the underwriters exercise their option to purchase additional
shares, or outstanding options and warrants </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
are exercised, you could experience further dilution. For a further description of the dilution that you will experience immediately after this offering, see the section titled
&#147;Dilution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws might discourage,
delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay, or prevent a merger,
acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by
our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our charter documents: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though
less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">eliminate cumulative voting in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those
shares, including preferences and voting rights, without stockholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created
directorship; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">prohibit stockholders from calling a special meeting of stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide for a staggered board, which will result in only a few directors being up for
<FONT STYLE="white-space:nowrap">re-election</FONT> in each calendar year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder
meetings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">authorize our board of directors, by a majority vote, to amend the bylaws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of our common stock to amend many of the
provisions described above; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">limit the liability of, and provide indemnification to, our directors and officers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, Section&nbsp;203 of the General Corporation Law of the State of Delaware (DGCL) prohibits a publicly-held Delaware corporation from
engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any provision
of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their
shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful
third-party claims against us and may reduce the amount of money available to us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and
amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, as permitted by Section&nbsp;145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into
with our directors and officers provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises
at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the
best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#146;s conduct was unlawful. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by
applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding,
except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings
initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into
indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to
directors, officers, employees and agents. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our amended and restated certificate of incorporation and amended and restated bylaws provide
that the Court of Chancery of the State of Delaware will be the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our
directors, officers or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the
Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for
any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the DGCL, our amended and restated certificate of incorporation or our
amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the
Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction,
such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws will also provide that the federal district courts of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and
arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws precludes stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court,
subject to applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds
favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal
securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that
a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue
other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision that will be contained
in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could
seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your
investment will depend on appreciation in the price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not currently intend to pay any cash dividends on our common
stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay
dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our
holders have purchased it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot specify with certainty the uses of the majority of the net proceeds we will receive from this offering. Our management will have broad
discretion in the application of the net proceeds, including for any of the purposes described in the section of this prospectus titled &#147;Use of Proceeds.&#148; Our management may spend a portion or all of the net proceeds from this offering in
ways that our stockholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively could seriously harm our business. Pending their use, we may invest the net proceeds from this
offering in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Participation in this offering by our existing stockholders and/or their affiliated
entities may reduce the public float for our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent certain of our existing stockholders and their affiliated entities
participate in this offering, such purchases would reduce the <FONT STYLE="white-space:nowrap">non-affiliate</FONT> public float of our shares, meaning the number of shares of our common stock that are not held by officers, directors and controlling
stockholders. A reduction in the public float could reduce the number of shares that are available to be traded at any given time, thereby adversely impacting the liquidity of our common stock and depressing the price at which you may be able to
sell shares of common stock purchased in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus and the documents incorporated by reference herein contain forward-looking statements concerning our business, operations and financial
performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be
forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148;
&#147;could,&#148; &#147;due,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;positioned,&#148;
&#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would&#148; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable
terminology. These forward-looking statements include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success, cost and timing of our development activities, preclinical studies and clinical trials, including our clinical
trials for <FONT STYLE="white-space:nowrap">4D-310,</FONT> <FONT STYLE="white-space:nowrap">4D-125,</FONT> <FONT STYLE="white-space:nowrap">4D-110,</FONT> 4D-150 and 4D-710; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the translation of our preclinical results and data into future clinical trials in humans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of any manufacturing runs for materials to be used in patient trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number, size and design of our planned clinical trials, and what regulatory authorities may require to obtain marketing
approval </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our preclinical and clinical
programs and business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations
and/or warnings in the label of any approved product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to develop and commercialize our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success of competing products or platform technologies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any product candidates
for which we obtain approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">future agreements with third parties in connection with the commercialization of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the size and growth potential of the markets for our product candidates, if approved for commercial use, and our ability to
serve those markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">existing regulations and regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the expected potential benefits of strategic collaboration agreements, including our relationship with uniQure, and our
ability to attract collaborators with development, regulatory and commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product
candidates and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential claims relating to our intellectual property and third-party intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to attract and retain key managerial, scientific and medical personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our financial performance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our anticipated use of the proceeds from this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other risks and uncertainties, including those listed under the section titled &#147;Risk Factors&#148; and the documents
incorporated by reference herein. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These forward-looking statements are based on management&#146;s current expectations,
estimates, forecasts and projections about our business and the industry in which we operate and management&#146;s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties
and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this prospectus may turn out to be inaccurate. Factors that may cause actual results to differ materially from current
expectations include, among other things, those listed under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus and the documents incorporated by reference herein. Potential investors are urged to consider these factors
carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this prospectus. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any
reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See the section titled
&#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_5"></A>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus contains estimates, projections and other information concerning our industry, our business, and the markets for our product candidates,
including data regarding the estimated patient population and market size for our product candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts,
projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly
stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and
similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type
appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that the net proceeds from the issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their option to purchase additional shares in full, based on the assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each $1.00 increase or decrease in the assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the net
proceeds to us from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the
same, and after deducting underwriting discounts and commissions. We may also increase or decrease the number of shares we are offering. Each increase or decrease of 1.0&nbsp;million shares in the number of shares we are offering would increase or
decrease, as applicable, the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the assumed public offering price stays the same. We do not expect that a change in the price to the public or the number of shares by these amounts would
have a material effect on the uses of the proceeds from this offering, although it may accelerate the time at which we will need to seek additional capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The principal purposes of this offering are to obtain additional capital to support our operations. We currently intend to use the net proceeds from
this offering, together with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund our ongoing and planned clinical and preclinical development of our product candidates, including ongoing clinical trials for 4D-310, 4D-125, <FONT
STYLE="white-space:nowrap">4D-150,</FONT> 4D-110 and 4D-710; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the further development and expansion of our pipeline including to complete lead optimization and <FONT STYLE="white-space:nowrap">IND-enabling</FONT>
studies for potentially other research candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any remaining amounts for working capital and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on our current operating plan, we estimate that our current cash and cash equivalents, together with the anticipated net proceeds from this
offering, will be sufficient to fund our operating expenses and capital expenditure requirements at least into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The amounts and timing of our actual expenditures and the extent of our research and development activities may vary significantly depending on numerous
factors, including the progress of our development efforts, the status of and results from any preclinical or clinical trials we may commence in the future, our ability to take advantage of expedited programs or to obtain regulatory approval for any
other product candidates we may identify and pursue, the timing and costs associated with the manufacture and supply of any other product candidates we may identify and pursue for clinical development or commercialization, and any unforeseen cash
needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may also use a
portion of the remaining net proceeds and our existing cash and cash equivalents to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current
commitments or obligations to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This expected use of the net proceeds from this offering represents our intentions based upon our
current plans and business conditions. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend
on the uses set forth above. If we receive any additional proceeds from this offering, we expect to use such proceeds on a proportional basis to the categories described above (other than funding for manufacturing capabilities and facilities). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pending their use, we intend to invest the net proceeds of this offering in a variety of capital-preservation investments, including short and
intermediate-term, interest-bearing, investment-grade securities, and government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings, if any,
to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and capitalization as of June&nbsp;30, 2021: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an as adjusted basis to give further effect to sale and issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering, assuming a public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should read this information together with our
consolidated financial statements and related notes incorporated by reference in this prospectus. For more details on how you can obtain our SEC reports and other information, you should read the section of the prospectus titled &#147;Where You Can
Find More Information.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June 30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except share<BR>and per share<BR>amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preferred stock, $0.0001 par value: 10,000,000 shares authorized and no shares issued or outstanding, actual
and as adjusted </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.0001 par value: 300,000,000&nbsp;shares authorized and as adjusted; 26,891,857 shares
issued and outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(159,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">240,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Each $1.00 increase or decrease in the assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, each of
the amount of our cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the
underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase or decrease of 1.0&nbsp;million in the number of shares offered by us would
increase or decrease, as applicable, each of the amount of our cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated
price range set forth on the cover page of this prospectus, remains the same, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. The as adjusted information discussed above is illustrative
only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock issued and outstanding as adjusted in the table above is based
on 26,891,857 shares of our common stock outstanding as of June 30, 2021, and excludes:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">4,238,519 shares of our common stock issuable upon the exercise of stock options to purchase common stock that were
outstanding as of June 30, 2021, with a weighted-average exercise price of $18.84 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">98,669 shares of our common stock issuable upon the exercise of outstanding warrants, with a weighted-average exercise
price of $6.76 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">183,600 shares of our common stock issuable upon the exercise of stock options to purchase common stock that were granted
after June 30, 2021, each with an exercise price of $28.55 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,726,365 shares of our common stock reserved for issuance pursuant to future awards under our 2020 Plan, as well as any
automatic increases in the number of shares of our common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">519,156 shares of our common stock reserved for issuance pursuant to future awards under our ESPP, as well as any automatic
increases in the number of shares of our common stock reserved for future issuance under this plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_9"></A>DILUTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your interest will be immediately diluted to the extent of the difference between the public offering
price per share of our common stock in this offering and the as adjusted net tangible book value per share of our common stock immediately after the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2021, our historical net tangible book value was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock. Our historical net tangible book value per share
represents total tangible assets less total liabilities divided by the number of shares of our common stock outstanding on June&nbsp;30, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
as adjusted net tangible book value represents our historical net tangible book value as adjusted to give effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common
stock in this offering at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We determine dilution per share to investors participating in this offering by subtracting as adjusted net tangible book value per share
after this offering from the assumed public offering price per share paid by investors participating in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table
illustrates this per share dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Historical net tangible book value per share as of June&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in as adjusted net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">As adjusted net tangible book value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each $1.00 increase or decrease in the assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, our as adjusted net tangible
book value as of June&nbsp;30, 2021 after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and would
increase or decrease dilution to investors in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase of 1.0&nbsp;million shares in the
number of shares we are offering would increase our as adjusted net tangible book value as of June 30, 2021 after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and would decrease dilution of investors in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share assuming the assumed
public offering price per share remains the same, and after deducting the underwriting discount and commissions and estimated offering expenses payable by us. Each decrease of 1.0&nbsp;million shares in the number of shares we are offering would
decrease our as adjusted net tangible book value as of June 30, 2021 after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and would increase dilution of investors in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share assuming the assumed
public offering price per share remains the same, and after deducting the underwriting discount and commissions and estimated offering expenses payable by us. The as adjusted information is illustrative only, and we will adjust this information
based on the actual public offering price and other terms of this offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the underwriters fully exercise their option to purchase additional shares, as adjusted net tangible
book value after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase in as adjusted net tangible book value per share to existing stockholders would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and the decrease in dilution to investors in this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that outstanding options with an exercise price per share that is less than the as adjusted net tangible book value per share are
exercised, new investors will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table shows, as of June 30, 2021, on an as adjusted basis, the number of shares of our common stock purchased from us, the total
consideration paid to us and the average price paid per share by existing stockholders and by new investors purchasing common stock in this offering, assuming a public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, before deducting the underwriting discounts and commissions and estimated
offering expenses payable by us (in thousands, except share and per share amounts and percentages): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price&nbsp;Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">New investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the underwriters were to fully exercise their option to purchase additional shares, the percentage of shares of our
common stock held by existing investors would be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%, and the percentage of shares of our common stock held by new investors would be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The foregoing tables and calculations (other than the historical net tangible book value calculation) are based on 26,891,857 shares of our common stock
outstanding as of June 30, 2021, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">4,238,519 shares of our common stock issuable upon the exercise of stock options to purchase common stock that were
outstanding as of June 30, 2021, with a weighted-average exercise price of $18.84 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">98,669 shares of our common stock issuable upon the exercise of outstanding warrants, with a weighted-average exercise
price of $6.76 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">183,600 shares of our common stock issuable upon the exercise of stock options to purchase common stock that were granted
after June 30, 2021, each with an exercise price of $28.55 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">2,726,365 shares of our common stock reserved for issuance pursuant to future awards under our 2020 Plan, as well as any
automatic increases in the number of shares of our common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">519,156 shares of our common stock reserved for issuance pursuant to future awards under our ESPP, as well as any automatic
increases in the number of shares of our common stock reserved for future issuance under this plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that outstanding options or warrants are exercised, new options or other securities are
issued under our equity incentive plans, or we issue additional shares of our common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of
market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of
these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth information relating to the beneficial ownership of our common stock as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of our
common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our named executives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The number of shares beneficially owned by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and
the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any
shares that the individual has the right to acquire within 60&nbsp;days after &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; through the exercise of any stock option, warrants
or other rights. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of our common stock held by that person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The percentage of shares beneficially owned is computed on the basis of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which reflects the automatic conversion of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our outstanding shares of redeemable convertible preferred stock into an equivalent number of shares of our common stock. Shares of our common
stock that a person has the right to acquire within 60&nbsp;days after &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are deemed outstanding for purposes of computing the
percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as
a group. Unless otherwise indicated below, the address for each beneficial owner listed is c/o 4D Molecular Therapeutics, Inc., 5858 Horton Street #455, Emeryville, California 94608. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Outstanding<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Exercisable<BR>Within<BR>60&nbsp;Days</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Owned<BR>After&nbsp;the<BR>Offering</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Beneficial<BR>Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>5% and Greater Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT>
LP(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><br><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities Affiliated with Fidelity(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Kirn, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">John F. Milligan, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Jacob Chacko, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Susannah Gray, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nancy Miller-Rich</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">David Schaffer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Charles Theuer, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shawn Cline Tomasello, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">August Moretti</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Robert Fishman, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">All executive officers and directors as a group (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:ARIAL; " ALIGN="left">Indicates beneficial ownership of less than 1% of our total outstanding common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:ARIAL; " ALIGN="left">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock held by Viking Global Opportunities Illiquid Investments&nbsp;Sub-Master&nbsp;LP (Opportunities Fund). Opportunities Fund has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its
general partner, Viking Global Opportunities Portfolio GP LLC (Opportunities GP), and by Viking Global Investors LP (VGI), which provides managerial services to Opportunities Fund. O. Andreas Halvorsen, David C. Ott and Rose Shabet, as Executive
Committee members of Viking Global Partners LLC (the general partner of VGI) and Opportunities GP, have shared authority to direct the voting and disposition of investments beneficially owned by the Opportunities Fund and Opportunities GP. The
business address of each of the entities is c/o&nbsp;Viking Global Investors LP, 55 Railroad Avenue, Greenwich, CT 06830. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:ARIAL; " ALIGN="left">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock directly held by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the &#147;FMR Reporters&#148;). FMR LLC has sole dipositive power with respect to all of the above shares and sole voting power
with respect to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the above shares. FMR LLC is a parent holding company in accordance with&nbsp;Section&nbsp;240.13d-1&nbsp;(b) (1) (ii)&nbsp;(G) of
the Exchange Act. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting
common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#146; voting agreement under which all Series B voting common shares will be
voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#146; voting agreement, members of the Johnson family may be deemed,
under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies
registered under the Investment Company Act of 1940 (&#147;Fidelity Funds&#148;) advised by Fidelity Management&nbsp;&amp; Research Company (&#147;FMR Co&#148;), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds&#146;
Boards of Trustees. FMR Co carries out the voting of the shares under written guidelines established by the Fidelity Funds&#146; Boards of Trustees. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation and our amended
and restated bylaws, the amended and restated investors&#146; rights agreement to which we and certain of our stockholders are parties and of the DGCL. Because the following is only a summary, it does not contain all of the information that may be
important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws and amended and restated investors&#146; rights agreement, copies of which have been filed as
exhibits to the registration statement of which this prospectus is part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our authorized capital stock consists of 300,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock,
$0.0001 par value per share. As of June&nbsp;30, 2021, there were outstanding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">26,891,857 shares of our common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, held by
approximately 31&nbsp;stockholders of record; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">4,238,519 shares of our common stock issuable upon exercise of outstanding stock options. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of
directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 66 2/3% of
the voting power of all of the then outstanding voting stock is required to take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, such as the provisions relating to amending our amended
and restated bylaws, the classified board and director liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if
any, as may be declared from time to time by our board of directors out of legally available funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in the net assets legally available
for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Rights and Preferences </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Holders of our common stock
have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may
designate in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Fully Paid and Nonassessable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">All of our outstanding shares of common stock are, and the shares of our common stock to be issued in this offering will be, fully paid and
nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more
series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund
terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of our
common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control or other
corporate action. As of June&nbsp;30, 2021, no shares of preferred stock are outstanding, and we have no present plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2021, we had outstanding options
to purchase 4,238,519 shares of our common stock, with a per share weighted-average exercise price of $18.84, under our 2020 Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2021, we had warrants outstanding with the option to purchase 98,669&nbsp;shares of our common stock, with a weighted-average
exercise price of $6.76 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under our amended and restated investors&#146; rights agreement, based on the number of shares outstanding as of June&nbsp;30, 2021, the holders of
11.6&nbsp;million shares of our common stock, or their transferees, have the right to require us to register their shares under the Securities Act so that those shares may be publicly resold, and the holders of 11.6&nbsp;million shares of our common
stock, or their transferees, have the right to include their shares in any registration statement we file, in each case as described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Demand
Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number of shares outstanding as of June&nbsp;30, 2021, after the consummation of this offering, the holders
of 11.6&nbsp;million shares of our common stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis), or their transferees, will be entitled to certain demand registration rights. The holders of at least 50%&nbsp;of these shares can,
on not more than two occasions, request that we register all or a portion of their shares if the aggregate price to the public of the shares offered is at least $30.0&nbsp;million (before deductions of underwriters&#146; commissions and expenses).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number of shares outstanding as of June&nbsp;30, 2021, in the event that we determine to register any of our securities under the Securities
Act (subject to certain exceptions), either for our own account or for the account of other security holders, the holders of 11.6&nbsp;million shares of our common stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis), or their
transferees, will be entitled to certain &#147;piggyback&#148; registration rights allowing the holders to include their shares in such registration, subject to certain marketing and other limitations. As a result, whenever we propose to file&nbsp;a
registration statement under the Securities Act, other than with respect to a registration related to employee benefit plans, the offer and sale of debt securities, or corporate reorganizations or certain other transactions, the holders of these
shares are entitled to notice of the registration and have the right, subject to limitations that the underwriters may impose on the number of shares included in the registration, to include their shares in the registration. In an underwritten
offering, the managing underwriter, if any, has the right, subject to specified conditions, to exclude or limit the number of shares such holders may include. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number of shares outstanding as of June&nbsp;30, 2021, the holders of 11.6&nbsp;million shares of our common stock (on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis), or their transferees, will be entitled to certain <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights. The holders of at least 30% of the registrable securities then
outstanding&nbsp;of these shares can make a written request that we register their shares on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> if we are eligible to file&nbsp;a registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and if the aggregate price to the public of the shares offered is at least $5.0&nbsp;million (before deductions of underwriters&#146; commissions and expenses). These stockholders may make an
unlimited number of requests for registration on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> but in no event shall we be required to file more than two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> in any given
twelve-month period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Expenses of Registration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
will pay the registration expenses of the holders of the shares registered pursuant to the demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights described above, including the expenses in an amount not to
exceed $25,000 of one special counsel for the selling holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights described above will expire, with respect to any
particular stockholder, upon the earlier of five years after the consummation of our initial public offering or when that stockholder can sell all of its shares under Rule&nbsp;144 of the Securities Act during any three-month period (and without the
requirement for us to be in compliance with the current public information required under Section c(1) of Rule 144 of the Securities Act). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-Takeover Effects
of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended and Restated Bylaws and Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain provisions of
Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us
by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be
in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These
provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an
unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware Anti-Takeover Statute </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to
Section&nbsp;203 of the DGCL, which prohibits persons deemed &#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly-held Delaware corporation for three years following the date these persons become
interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested
stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a
&#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to
transactions not approved in advance by our board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Undesignated Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The ability to authorize
undesignated preferred stock will make it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may
have the effect of deterring hostile takeovers or delaying changes in control or management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Special Stockholder Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws provide that a special meeting of stockholders may be called at any time by our board of directors, or our President or
Chief Executive Officer, but such special meetings may not be called by our stockholders or any other person or persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Requirements for Advance
Notification of Stockholder Nominations and Proposals </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated bylaws established advance notice procedures with respect to
stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws do not provide for the right of stockholders to act by written
consent without a meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Classified Board; Election and Removal of Directors; Filling Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our board of directors is divided into three classes. The directors in each class serve for a three-year term, one class being elected each year by our
stockholders, with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do
not have cumulative voting rights, our stockholders holding a majority of the shares of our common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
stock outstanding are able to elect all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause and requires a
stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. For more information on the classified board, see the section titled &#147;Management&#151;Board Composition&#148; in our Definitive
Proxy Statement on Schedule 14A, filed with the SEC on April 6, 2021. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board of directors, may only be filled by
a resolution of our board of directors unless our board of directors determines that such vacancies shall be filled by our stockholders. This system of electing and removing directors and filling vacancies may tend to discourage a third party from
making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Choice of Forum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate
of incorporation and amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or
proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or stockholders to us or to our
stockholders; any action asserting a claim against us arising pursuant to the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended from time to time); or any action asserting a
claim against us that is governed by the internal affairs doctrine. As a result, any action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of Delaware and cannot be
filed in any other jurisdiction; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction;
and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of
Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a
cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws preclude stockholders that
assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If any action the subject
matter of which is within the scope described above is filed in a court other than a court located within the State of Delaware, or a Foreign Action, in the name of any stockholder, such stockholder shall be deemed to have consented to the personal
jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and amended and
restated bylaws and having service of process made upon such stockholder in any such action by service upon such stockholder&#146;s counsel in the Foreign Action as agent for such stockholder. Although our amended and restated certificate of
incorporation and amended and restated bylaws will contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is
unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable
for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Amendment of Charter Provisions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The amendment of any
of the above provisions in our amended and restated certificate of incorporation, except for the provision making it possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the
holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The provisions of the DGCL, our amended and restated
certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common
stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions
that stockholders may otherwise deem to be in their best interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest
extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DCGL; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Each of our amended and restated certificate of incorporation and amended and restated bylaws provides that we are required to indemnify our directors
and officers, in each case to the fullest extent permitted by Delaware law. Our amended and restated bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and
permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under
Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With specified exceptions, these agreements provide for
indemnification for related expenses including, among other things, attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and
indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may
discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if
successful, might benefit us and our stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damages. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our
common stock is listed on the Nasdaq Global Market under the symbol &#147;FDMT.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. The transfer agent and registrar&#146;s
address is 6201 15th Avenue, Brooklyn, New York 11219. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Future sales of our common stock, including shares issued upon the exercise of outstanding options or warrants, in the public market after this
offering, or the perception that those sales may occur, could cause the prevailing market price for our common stock to fall or impair our ability to raise equity capital in the future. As described below, only a limited number of shares of our
common stock will be available for sale in the public market for a period of several months after consummation of this offering due to contractual and legal restrictions on resale described below. Future sales of our common stock in the public
market either before (to the extent permitted) or after restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price of our common stock at such time and our ability to raise equity capital at
a time and price we deem appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale of Restricted Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number of shares of our common stock outstanding as of June&nbsp;30, 2021, upon the consummation of this offering and assuming no exercise
of the underwriters&#146; option to purchase additional shares, we will have outstanding an aggregate of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock. Of these
shares, all of the shares of common stock to be sold in this offering, and any shares sold upon exercise of the underwriters&#146; option to purchase additional shares, will be freely tradable in the public market without restriction or further
registration under the Securities Act, unless the shares are held by any of our &#147;affiliates&#148; as such term is defined in Rule&nbsp;144 of the Securities Act. All remaining shares of common stock held by existing stockholders immediately
prior to the consummation of this offering will be &#147;restricted securities&#148; as such term is defined in Rule&nbsp;144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are
eligible for public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule&nbsp;144 or Rule&nbsp;701, which rules are summarized
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with this offering, we, our executive officers and our directors have agreed, subject to certain exceptions, with the underwriters not to
dispose of or hedge any shares of our common stock or securities convertible into or exchangeable for shares of our common stock during the period from the date of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement continuing through the
date &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;days after the date of this prospectus, except with the prior written consent of Goldman Sachs &amp; Co. LLC on behalf of the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Certain of our employees, including our executive officers have entered into written trading plans that are intended to comply with Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act. Sales under these trading plans would not be permitted until the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements relating to the offering described above.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Following the <FONT STYLE="white-space:nowrap">lock-up</FONT> periods set forth in the agreements described above, and assuming that Goldman
Sachs&nbsp;&amp; Co. LLC does not release any parties from these agreements, all of the shares of our common stock that are restricted securities or are held by our affiliates as of the date of this prospectus will be eligible for sale in the public
market in compliance with Rule&nbsp;144 under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule&nbsp;144, as currently in effect, once we have been subject to the public company reporting requirements of the Exchange Act for
at least 90&nbsp;days, a person (or persons whose shares are required to be aggregated) who is not deemed to have been one of our &#147;affiliates&#148; for purposes of Rule&nbsp;144 at any time during the three months preceding a sale, and who has
beneficially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
owned restricted securities within the meaning of Rule&nbsp;144 for at least six months, including the holding period of any prior owner other than one of our &#147;affiliates,&#148; is entitled
to sell those shares in the public market (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to above, if applicable) without complying with the manner of sale, volume limitations or notice provisions of
Rule&nbsp;144, but subject to compliance with the public information requirements of Rule&nbsp;144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other
than &#147;affiliates,&#148; then such person is entitled to sell such shares in the public market without complying with any of the requirements of Rule&nbsp;144 (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to
above, if applicable). In general, under Rule&nbsp;144, as currently in effect, once we have been subject to the public company reporting requirements of the Exchange Act for at least 90&nbsp;days, our &#147;affiliates,&#148; as defined in
Rule&nbsp;144, who have beneficially owned the shares proposed to be sold for at least six months are entitled to sell in the public market, upon expiration of any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and within any
three-month period, a number of those shares of our common stock that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1% of the number of shares of common stock then outstanding, which will equal approximately [<FONT
STYLE="font-family:Times New Roman">&#149;</FONT>] shares of our common stock immediately after this offering (calculated as of June 30, 2021 on the basis of the assumptions (i)-(iii)&nbsp;described above); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the average weekly trading volume of our common stock on The Nasdaq Global Select Market during the four calendar weeks
preceding the filing of a notice on Form&nbsp;144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Such sales under Rule&nbsp;144 by our
&#147;affiliates&#148; or persons selling shares on behalf of our &#147;affiliates&#148; are also subject to certain manner of sale provisions, notice requirements and to the availability of current public information about us. Notwithstanding the
availability of Rule&nbsp;144, the holders of substantially all of our restricted securities have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as referenced above and their restricted securities will become eligible for
sale (subject to the above limitations under Rule&nbsp;144) upon the expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In general, under Rule 701 as currently in effect, any of our employees, directors, officers, consultants or advisors who acquired common stock from us
in connection with a written compensatory stock or option plan or other written agreement in compliance with Rule 701 under the Securities Act are entitled to rely on Rule 701 to resell such shares beginning 90 days after the effective date of this
public offering, but without compliance with the holding period requirements contained in Rule 144. Accordingly, subject to any applicable lock-up agreements, under Rule 701 persons who are not our &#147;affiliates,&#148; as defined in Rule 144, may
resell those shares without complying with the minimum holding period or public information requirements of Rule 144, and persons who are our &#147;affiliates&#148; may resell those shares without compliance with Rule 144&#146;s minimum holding
period requirements (subject to the terms of the lock-up agreement referred to above). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Based on the number of shares outstanding as of June 30, 2021, after the consummation of this offering, the holders of 11.6&nbsp;million shares of our
common stock, or their transferees, will, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements referred to above, be entitled to certain rights with respect to the registration of the offer and sale of those shares under the
Securities Act. For a description of these registration rights, see the section titled &#147;Description of Capital Stock&#151;Registration Rights.&#148; If the offer and sale of these shares are registered, they will be freely tradable without
restriction under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stock Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We
have filed with the SEC a registration statement under the Securities Act covering the shares of common stock that we may issue upon exercise of outstanding options reserved for issuance under our 2015 Equity Incentive Plan and our 2020 Plan. Shares
registered under such registration statement are available for sale in the open market, subject to Rule&nbsp;144 volume limitations and the lock-up agreements described above, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following discussion is a summary of the material U.S. federal income tax consequences
to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax
effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S. Internal
Revenue Code of 1986, as amended (the Code), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may
change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder. We have not sought and
will not seek any rulings from the Internal Revenue Service (the IRS) regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the
purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion
transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">banks, insurance companies, and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors
therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If an entity treated as a partnership for U.S. federal income tax
purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding
our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION
OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>
ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Definition of
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For purposes of this discussion, a
<FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common stock that is neither a &#147;U.S. person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is
any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a trust that (i)&nbsp;is subject to the primary supervision of a U.S. court and all substantial decisions of which are
subject to the control of one or more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (ii)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax
purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As described
in the section titled &#147;Dividend Policy,&#148; we do not anticipate paying any cash dividends in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends
for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will
constitute a return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will
be treated as described below under &#147;&#151;Sale or Other Taxable Disposition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Subject to the discussion below on effectively connected
income, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax
treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT>
(or other applicable documentation) certifying qualification for the lower treaty rate). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate,
may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits
under any applicable tax treaties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with
the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a
permanent establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any such effectively connected
dividends will be subject to U.S. federal income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such
lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax
treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale or Other Taxable Disposition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other
taxable disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a
trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States
for 183&nbsp;days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our common stock constitutes a U.S. real property interest (USRPI) by reason of our status as a U.S. real property holding
corporation (USRPHC) for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Gain described in the first bullet point above generally will be
subject to U.S. federal income tax on a net income basis at the regular rates applicable to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30%
(or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A Non-U.S.
Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon the sale or other taxable disposition of our common
stock, which may be offset by certain U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is not considered a resident of the United States), provided the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">With respect to the
third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of
our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain
arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury
Regulations, on an established securities market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date
of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting and Backup Withholding </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Payments of
distributions on our common stock will not be subject to backup withholding, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid
IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However,
information returns are required to be filed with the IRS in connection with any distributions on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether such distributions constitute dividends or
whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding
or information reporting if the applicable withholding agent receives the certification described above or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder otherwise establishes an exemption.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Proceeds of a disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker that does
not have certain enumerated relationships with the United States generally will not be subject to backup withholding or information reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the
tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Backup withholding
is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the
required information is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Withholding taxes may be imposed under Sections&nbsp;1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance
Act (FATCA)) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed
on dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a
<FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (i)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (ii)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (iii)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to
the diligence and reporting requirements in (i)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States
persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT>
foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on our common
stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of our common stock on or after January&nbsp;1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments
of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common
stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and the underwriters have entered into an underwriting agreement with respect to the shares being offered. Subject to certain conditions, the
underwriters have agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC is the representative of the underwriters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the
shares covered by the option described below unless and until this option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have an option to buy up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise
that option for 30 days from the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table shows the per share and total underwriting discounts and commissions
to be paid to the underwriters by us. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to buy up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares sold by the underwriters to the public will initially be offered at the initial public offering price set forth
on the cover page of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share from the
initial public offering price. After the initial offering of the shares, Goldman Sachs &amp; Co. LLC may change the offering price and the other selling terms. The offering of the shares by the underwriters are subject to receipt and acceptance and
subject to the underwriters&#146; right to reject any order in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and our executive officers, directors, and certain of our
securityholders have agreed or will agree with the underwriters, subject to certain exceptions, not to dispose of or hedge any of our or their common stock or securities convertible into or exchangeable for shares of our common stock during the
period from the date of this prospectus continuing through the date &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;days after the date of this prospectus, except with the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC. This agreement does not apply to any
existing employee benefit plans. See the section titled &#147;Shares Eligible for Future Sale&#148; for a discussion of certain transfer restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;FDMT.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the offering, the underwriters may purchase and sell shares of our common stock in the open market. These transactions may include
short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering, and a short position
represents the amount of such sales that have not been covered by subsequent purchases. A &#147;covered short position&#148; is a short position that is not greater than the amount of additional shares for which the underwriters&#146; option
described above may be exercised. The underwriters may cover any covered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
short position by either exercising their option or purchasing shares in the open market. In determining the source of shares to cover the covered short position, the underwriters will consider,
among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above. &#147;Naked&#148; short sales are any short sales that
create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such naked short position by purchasing shares in the open market. A naked short position is
more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing
transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting
discount received by them because Goldman Sachs &amp; Co. LLC has repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for its own accounts, may have the
effect of preventing or retarding a decline in the market price of our common stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of our common stock. As a result, the price of our
common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on The
Nasdaq Global Select Market, in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;over-the-counter&nbsp;market</FONT></FONT> or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that our share of the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters for certain of its expenses in an amount up to $20,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters and their affiliates are full service financial institutions engaged in various activities, which may include sales and trading,
commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial <FONT STYLE="white-space:nowrap">and&nbsp;non-financial&nbsp;activities</FONT> and
services. The underwriters and their affiliates may in the future provide a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which they will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary course of its various business activities, the underwriters and their affiliates, officers, directors and employees may purchase, sell
or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for its own account and for the accounts of its customers, and such investment and
trading activities may involve or relate to assets, securities or instruments of the issuer (directly, as collateral securing other obligations or otherwise) or persons and entities with relationships with the issuer. The underwriters and their
affiliates may also communicate independent investment recommendations, market color or trading ideas or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to
clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Economic Area </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In relation to each Member State of the European Economic Area (each a &#147;Relevant State&#148;), no shares have been offered or will be offered
pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another
Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that the shares may be offered to the public in that Relevant State at any time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>provided</I> that no such offer of the shares shall require the company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an
&#147;offer to the public&#148; in relation to the shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to
decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in
relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>provided</I> that no such offer of the shares shall require the company or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or
supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer
to the public&#148; in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to
purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Canada </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
shares may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or
subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions, and Ongoing Registrant Obligations. Any
resale of the shares must be made in accordance with an exemption form, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or
territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts <FONT
STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in
connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Hong Kong </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may
not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the
Laws of Hong Kong) (Companies (Winding Up and Miscellaneous Provisions) Ordinance) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (Securities and
Futures Ordinance), or (ii)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of
issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than
with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Singapore </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus has not been registered as a
prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or
distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as defined under
Section&nbsp;4A of the Securities and Futures Act, Chapter 289 of Singapore (the SFA)) under Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or
any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of
the SFA, in each case subject to conditions set forth in the SFA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person
which is a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an
accredited investor, the securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the shares under Section&nbsp;275 of the SFA except: (i)&nbsp;to an
institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (ii)&nbsp;where such transfer arises from an offer in that corporation&#146;s securities pursuant to
Section&nbsp;275(1A) of the SFA, (iii)&nbsp;where no consideration is or will be given for the transfer, (iv)&nbsp;where the transfer is by operation of law, (v)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (vi)&nbsp;as specified in
Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore (Regulation 32). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where
the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and
each beneficiary of the trust is an accredited investor, the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the
SFA except: (i)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (ii) where such transfer arises from an offer that is made on terms that such rights or
interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (iii) where no
consideration is or will be given for the transfer, (iv)&nbsp;where the transfer is by operation of law, (v)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (vi)&nbsp;as specified in Regulation 32. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Solely for the purposes of its obligations pursuant to Section&nbsp;309B of the SFA, we have determined, and hereby notify all relevant persons (as
defined in the CMP Regulations 2018), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice
<FONT STYLE="white-space:nowrap">SFA&nbsp;04-N12:&nbsp;Notice</FONT> on the Sale of Investment Products and MAS <FONT STYLE="white-space:nowrap">Notice&nbsp;FAA-N16:&nbsp;Notice</FONT> on Recommendations on Investment Products). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Japan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares have not been and will not be registered
under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as amended) (the FIEA). The shares may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any
person resident in Japan or any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant to an exemption
from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Australia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission (ASIC), in relation to the offering. This offering document does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the Corporations Act), and does not
purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Any offer in Australia of the shares may only be made to persons (the Exempt Investors) who are
&#147;sophisticated investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the
Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months
after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or
where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such <FONT STYLE="white-space:nowrap">Australian&nbsp;on-sale&nbsp;restrictions.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This offering document contains general information only and does not take account of the investment objectives, financial situation or particular needs
of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this offering document is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Dubai International Financial Centre </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This offering document relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (DFSA). This
offering document is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying
any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth in this prospectus and has no responsibility for the offering document. The shares to which this offering
document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this offering document you
should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have not and will not register with the Swiss Financial Market Supervisory Authority (FINMA) as a foreign collective investment scheme pursuant to
Article 119 of the Federal Act on Collective Investment Scheme of 23&nbsp;June 2006, as amended (CISA), and accordingly the shares being offered pursuant to this prospectus have not and will not be approved, and may not be licenseable, with FINMA.
Therefore, the shares have not been authorized for distribution by FINMA as a foreign collective investment scheme pursuant to Article 119 CISA and the shares offered hereby may not be offered to the public (as this term is defined in Article 3
CISA) in or from Switzerland. The shares may solely be offered to &#147;qualified investors,&#148; as this term is defined in Article 10 CISA, and in the circumstances set out in Article 3 of the Ordinance on Collective Investment Scheme of
22&nbsp;November 2006, as amended (CISO), such that there is no public offer. Investors, however, do not benefit from protection under CISA or CISO or supervision by FINMA. This prospectus and any other materials relating to the shares are strictly
personal and confidential to each offeree and do not constitute an offer to any other person. This prospectus may only be used by those qualified investors to whom it has been handed out in connection with the offer described in this prospectus and
may neither directly or indirectly be distributed or made available to any person or entity other than its recipients. It may not be used in connection with any other offer and shall in particular not be copied and/or distributed to the public in
Switzerland or from Switzerland. This prospectus does not constitute an issue prospectus as that term is understood pursuant to Article 652a and/or 1156 of the Swiss Federal Code of Obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
We have not applied for a listing of the shares on the SIX Swiss Exchange or any other regulated securities market in Switzerland, and consequently, the information presented in this prospectus
does not necessarily comply with the information standards set out in the listing rules of the SIX Swiss Exchange and corresponding prospectus schemes annexed to the listing rules of the SIX Swiss Exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, Menlo Park,
California. Cooley LLP, San Francisco, California, is acting as counsel for the underwriters in connection with this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_22">
</A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The financial statements incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December
31, 2020 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_23"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> under the Securities Act with respect to
the shares of our common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith.
For further information with respect to 4D Molecular Therapeutics, Inc. and the common stock offered hereby, reference is made to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus
regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract
or other document filed as an exhibit to the registration statement. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address
is www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are subject to the information and periodic reporting requirements of the Exchange Act and, in accordance therewith, file
periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information are available for inspection and copying at the public reference room and website of the SEC referred to above. We
maintain a website at www.4dmoleculartherapeutics.com. You may access our annual reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,</FONT> current reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such
material is electronically filed with, or furnished to, the SEC. The reference to our website address does not constitute incorporation by reference of the information contained on our website, and you should not consider the contents of our website
in making an investment decision with respect to our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc162874_24"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can disclose important information
to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to
the date of this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File No.
001-39782): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1650648/000156459021015502/fdmt-10k_20201231.htm">Form
 10-K</A> for the year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;25, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Quarterly Reports on Form&nbsp;10-Q for the quarters ended March&nbsp;31, 2021 and June&nbsp;30, 2021, filed with the
SEC on May&nbsp;13, 2021 and August&nbsp;12, 2021, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Current Reports on Form 8-K, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520318186/d13863d8k.htm">
</A><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312521094446/d118367d8k.htm"></A>May&nbsp;20, 2021, June&nbsp;25, 2021 and September 24, 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312521107762/d155968ddef14a.htm">Schedule
 14A</A>, filed with the SEC on April 6, 2021; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563ds1a.htm">Form
 S-1</A> filed with the SEC on December 7, 2020, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Notwithstanding the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information that we have
&#147;furnished&#148; to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We will furnish without charge to you, on
written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents to 4D Molecular Therapeutics, Inc., Attn: Corporate
Secretary, 5858 Horton Street #455, Emeryville, California, 94608. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">You also may access these filings on our website at www.4dmoleculartherapeutics.com. We do not
incorporate the information on our website into this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or any supplement to this
prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Any
statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or replaced for purposes of this prospectus to the extent that a statement contained in this prospectus
modifies, supersedes or replaces such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common
Stock </P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g162874g92m89.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<TD VALIGN="top" ALIGN="center"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II&nbsp;INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Item&nbsp;13. Other Expenses of Issuance and Distribution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by the registrant in connection
with the sale of common stock being registered. All amounts are estimates except for the SEC registration fee, the Financial Industry Regulatory Authority, Inc. (FINRA) filing fee and The Nasdaq Global Select Market listing fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Item</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;paid<BR>or to<BR>be paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">The Nasdaq Global Select Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Blue Sky, qualification fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transfer Agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">To be completed by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Item&nbsp;14. Indemnification of Directors and Officers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As permitted by Section&nbsp;102 of the Delaware General Corporation Law, we have adopted provisions in our amended and restated certificate of
incorporation and amended and restated bylaws that will limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the
corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of
fiduciary duty as a director, except for liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our amended and restated
certificate of incorporation will also authorize us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As permitted by Section&nbsp;145 of the Delaware General Corporation Law, our amended and restated bylaws provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may indemnify our directors, officers, and employees to the fullest extent permitted by the Delaware General Corporation
Law, subject to limited exceptions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest
extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation provides for the indemnification provisions described above and elsewhere herein. We have entered
into separate indemnification agreements with our directors and officers which may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require us,
among other things, to indemnify our officers and directors against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements
also generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. In addition, we have purchased a policy of directors&#146; and officers&#146;
liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in some circumstances. These indemnification provisions and the indemnification agreements may be sufficiently broad to
permit indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The form of Underwriting Agreement, to be attached as Exhibit&nbsp;1.1 hereto, provides for indemnification by the underwriters of us and our officers
who sign this Registration Statement and directors for specified liabilities, including matters arising under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Item&nbsp;15. Recent Sales
of Unregistered Securities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following list sets forth information as to all securities we have sold since January&nbsp;1, 2017, which
were not registered under the Securities Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In May 2018, we issued a warrant to purchase 23,669 shares of our common stock at a per share exercise price of $3.19.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In August 2018, we issued in a series of transactions an aggregate of 5,154,632 shares of our Series B redeemable
convertible preferred stock at a price per share of $17.46 for aggregate proceeds to us of $89,999,874.72. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In April through June 2020, we issued, in a series of transactions an aggregate of 4,200,353 shares of our Series C
redeemable convertible preferred stock at a price per share of $18.00 for aggregate gross proceeds to us of $75,606,354.00. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">We granted stock options and stock awards to employees, directors and consultants under our 2015 Equity Incentive Plan,
covering 4,075,756 shares of common stock, at a weighted-average exercise price of $10.66 per share. Of these, options covering an aggregate of 928,968 shares of common stock were cancelled without being exercised. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In December 2020, we issued a warrant to purchase 30,000 shares of our common stock at a per share exercise price of
$18.00. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In April 2021, we issued a warrant to purchase 40,000 shares of our common stock at a per share exercise price of $9.41.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">In October 2021, we issued, pursuant to a stock purchase agreement, 125,715 shares of common stock at a price per share
of $31.82 for aggregate proceeds to us of $3,999,999.87. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We claimed exemption from registration under the Securities Act for the
sale and issuance of securities in the transactions described in paragraphs&nbsp;(1) through (3) and (7)&nbsp;by virtue of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Section&nbsp;4(a)(2) and/or Regulation&nbsp;D promulgated thereunder as transactions not involving any public offering. All of the purchasers of unregistered securities for which we relied on
Section&nbsp;4(a)(2) and/or Regulation&nbsp;D represented that they were accredited investors as defined under the Securities Act. We claimed such exemption on the basis that (a)&nbsp;the purchasers in each case represented that they intended to
acquire the securities for investment only and not with a view to the distribution thereof and that they either received adequate information about the registrant or had access, through employment or other relationships, to such information and
(b)&nbsp;appropriate legends were affixed to the stock certificates issued in such transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We claimed exemption from registration under the
Securities Act for the sales and issuances of securities in the transactions described in paragraph&nbsp;(4) above under Section&nbsp;4(a)(2) of the Securities Act in that such sales and issuances did not involve a public offering or under
Rule&nbsp;701 promulgated under the Securities Act, in that they were offered and sold either pursuant to written compensatory plans or pursuant to a written contract relating to compensation, as provided by Rule&nbsp;701. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Item&nbsp;16. Exhibits and Financial Statement Schedules. </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Exhibits. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Incorporated&nbsp;by&nbsp;Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Exhibit Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Filed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Herewith</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520318186/d13863dex31.htm">Amended and Restated Certificate of Incorporation, as currently in effect. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12/15/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520318186/d13863dex32.htm">Amended and Restated Bylaws, as currently in effect. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12/15/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001650648/000156459021015502/fdmt-ex41_2911.htm">Description of Securities of the Registrant. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10-K</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">3/25/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex42.htm">Form of Common Stock Certificate. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12/7/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex43.htm">Amended and Restated Investors&#146; Rights Agreement, dated as of April 29, 2020, among the Registrant and the investors party thereto.
</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12/7/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Latham&nbsp;&amp; Watkins LLP.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1(a)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520296146/d69563dex101a.htm">2015 Equity Incentive Plan. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">11/17/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="bottom">(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1(b)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520296146/d69563dex101b.htm">Form of Stock Option Agreement under 2015 Equity Incentive Plan. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">11/17/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="bottom">(b)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2(a)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001650648/000119312520318232/d28592dex992a.htm">2020 Incentive Award Plan. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12/15/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99.2</TD>
<TD NOWRAP VALIGN="bottom">(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2(b)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex102b.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12/7/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">(b)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2(c)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex102c.htm">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2020 Incentive Award Plan. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12/7/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">(c)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2(d)#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex102d.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2020 Incentive Award Plan.</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12/7/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">(d)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001650648/000119312520318232/d28592dex993.htm">2020 Employee Stock Purchase Plan. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">12/15/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Incorporated&nbsp;by&nbsp;Reference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Exhibit Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Filed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Herewith</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex104.htm">Form of Indemnification Agreement for directors and officers. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/7/20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520296146/d69563dex105.htm">Collaboration and License Agreement, dated November&nbsp;
16, 2017, among the Registrant, F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd and <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Inc. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11/17/20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520296146/d69563dex106.htm">Amended and Restated Collaboration and License Agreement, dated August&nbsp;6, 2019, between the Registrant and uniQure biopharma B.V.
</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11/17/20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520296146/d69563dex107.htm">Collaboration and License Agreement, dated August&nbsp;6, 2019, by and between the Registrant and uniQure biopharma B.V. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11/17/20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex108.htm">Exclusive License and Bailment Agreement, dated December 19, 2013, between the Registrant and The Regents of the University of California.
</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/7/20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex109.htm">Exclusive License and Bailment Agreement, dated December 19, 2013, between the Registrant and The Regents of the University of California.
</A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/7/20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex1010.htm">Offer Letter, dated March&nbsp;20, 2015 between David Kirn, M.D. and the Registrant. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/7/20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex1011.htm">Employment Agreement, dated January&nbsp;15, 2019 between Peter Francis, M.D., Ph.D. and the Registrant. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/7/20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12#&#134;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex1012.htm">Offer Letter, dated January&nbsp;4, 2019 between August Moretti and the Registrant. </A></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/7/20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of independent registered public accounting firm.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Latham&nbsp;&amp; Watkins&nbsp;LLP (included in Exhibit&nbsp;5.1).</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Power of Attorney. Reference is made to the signature page to the Registration Statement.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Financial Statement Schedules. All financial statement schedules are omitted because the information required to be set
forth therein is not applicable or is shown in the financial statements or the notes thereto. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Item&nbsp;17. Undertakings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the payment by the Registrant of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of
whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The undersigned Registrant hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus
filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this
Registration Statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such
denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Confidential Treatment Requested by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>4D Molecular Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in Emeryville, California on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>4D Molecular Therapeutics, Inc.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">David Kirn, M.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints
David Kirn, M.D. and August Moretti, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to
this Registration Statement, including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought, and to file the
same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing
requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or
substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act, this Registration Statement
has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">David Kirn, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Chief&nbsp;Executive&nbsp;Officer and Director</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><I>(Principal
Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">August J. Moretti</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL"><I>(Principal Financial and Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">John F. Milligan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Jacob Chacko, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Susannah Gray</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Nancy Miller-Rich</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">David Schaffer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Charles P. Theuer, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Shawn Cline Tomasello, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g162874g44t14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g162874g44t14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1C44&AO=&]S:&]P(#,N,  X0DE-! 0
M    &+B^8R@X0DE-! 0      "D< 5H  QLE1QP"   "   < @4 %49I9W5R
M93-!7U!I<&5L:6YE7W8Q,P X0DE-!"4      !";+NAZ/\$SYCW#%VDS#UPJ
M.$))300Z      $9    $     $       MP<FEN=$]U='!U=     4
M4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    ; $( <@!O
M '0 : !E '( ( !- $8 0P M $P ,@ W #4 , !$ %< ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              RD   =D          $
M 0             '9    RD                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   RD     4F=H=&QO;F<   =D    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    "CA"24T$#      . P    $   "@    1
M >   '^    -YP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 1 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
MS,[*O^W9LY#P\9>1 =D9#/:+K&M9Z=<L:W;^ZJ-^=F;HJNR&;1!VWW/#CSO!
M<[^RNHRK*&Y^5ZGIEPR<C<'ML)UML@N+/:H]*#6]7Z?LM]2<FN8#FQ[A^_\
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M=M42G&/S2 OOH^6>KE\?M.S_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                            _^%&$FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED
M/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN
M<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@
M-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @
M(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R
M96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R(#(U+C,@*$UA8VEN=&]S:"D\
M+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P
M,C$M,3 M,#=4,3(Z,C<Z-#(M,#<Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @
M(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TQ,"TP-U0Q,SHS-CHS."TP-SHP
M,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E
M/C(P,C$M,3 M,#=4,3,Z,S8Z,S@M,#<Z,# \+WAM<#I-971A9&%T841A=&4^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R871O
M<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @
M(" @(" @/&EL;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L/D%D;V)E($EL;'5S
M=')A=&]R/"]I;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O
M97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @
M(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG
M/2)X+61E9F%U;'0B/D9I9W5R93-!7U!I<&5L:6YE7W8Q,SPO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z
M<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @
M(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N
M9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD
M:60Z-D%!-$(R,30X,#(W14,Q,4)!-49!1# W0C4Y13DQ1#$\+WAM<$U-.D1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z
M,S,X1C,X,T5!13(W14,Q,4)!-49!1# W0C4Y13DQ1#$\+WAM<$U-.DEN<W1A
M;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I
M9#ID,C0V-V,P92TX-&$Q+3@R-&4M.68U-2TR8SEF,&5C8V4Q-C$\+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D1E<FEV961&
M<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T
M4F5F.FEN<W1A;F-E240^>&UP+FEI9#HS,CA&,S@S14%%,C=%0S$Q0D$U1D%$
M,#="-3E%.3%$,3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T
M4F5F.F1O8W5M96YT240^>&UP+F1I9#HV04$T0C(Q-#@P,C=%0S$Q0D$U1D%$
M,#="-3E%.3%$,3PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.F0R-#8W8S!E+3@T83$M.#(T
M92TY9C4U+3)C.68P96-C93$V,3PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO
M<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E
M9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#HW868S9#@W-"UA93$Y+31C,F4M.&-C-"TW
M9&(U-#DV.#,W,S$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C M,#DM,314,C$Z,3 Z,C M,#<Z,# \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R(#(T+C(@*$UA8VEN=&]S:"D\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C8Y031",C$T.# R-T5#,3%"035&040P-T(U.44Y,40Q
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(Q+3$P+3 W5#$S.C,V.C X+3 W.C P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&EM
M86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E
M<G,^8V]N=F5R=&5D(&9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HV04$T0C(Q-#@P,C=%0S$Q
M0D$U1D%$,#="-3E%.3%$,3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,"TP-U0Q,SHS-CHP."TP-SHP
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C,R.$8S.#-%044R-T5#,3%"035&040P-T(U.44Y,40Q
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(Q+3$P+3 W5#$S.C,V.C,X+3 W.C P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E
M<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O
M<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS,SA&,S@S14%%,C=%0S$Q
M0D$U1D%$,#="-3E%.3%$,3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,"TP-U0Q,SHS-CHS."TP-SHP
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES
M=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z
M4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,34N,# \+W!D9CI0<F]D=6-E
M<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @
M(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO
M9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO
M>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\
M/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@! P)= P$1  (1 0,1 ?_$ !\
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MBQ[GYT&'>7W>L;M]K4;S2':CZ1WY?Y?_ +>.&M<[+Z$\T.SX\*=N_9$Q>_\
M<@P[N_D-J=YI#M2O2.^W#6N=E]">:(#P^7"G<WGB8O>/-^=!AWF#G_P&#E]C
M?V^X&F\TAVI7I'?;\OX&;6N=E]">:(]GRX4WUQ,7R<_YT&'>?=S?WC>SS_>[
MC>:0[4KQ_E'?;R^F&M<[+Z$\T.SY<*;ZXF,#_P (,.[_ .0_S_>;S2':E>E<
M]N&M<[+Z$\T0'A\N%.#=_=$18_\ A!AWR&[OV?=U&\TAVH^D=]N&M<[+Z$\T
M?79\N%-]<3&>)_#OL_Y#ZG>:0X6E>D=]LPUKG9?0GFB'9\N%- !$=HB,Y-_^
M*##O+_N/^+VM0:/( $ZI65S^==]N&M<[+Z$\T5RQ</-PHC!^W0:[0L8DDI!5
M=Z8HXCQ ?>YDZS$23P_1'HYC "CMVNH!-X$3 P)I@5,I2A2FD2!3=3*AFH'\
MH[P*4!_*RV#ZMI@75\"N ; GB\D4+L^G"F;@_NB8OE_S08=^_P#F&YO<W^QJ
MK>BG=K/I7/IZ_FAK7.R^A/-$.SZ<*9ZXF+\4&'O9_P A?:]GEYM0:13A:[:N
M/\X[GY.NYX:USLOH3S1]!P^7"FC_ .\3%[NU^=!AWFW?[#?/]^K>>GG/5*M_
MG7?;AK7.R^A/-#L^7"F[]P[1$7XH,.^0P#W?L:;S2':E>E<]N&M<[+Z$\T!X
M?+A3>7^Z(C.0-_ZS^'?(;GTWFD.U*V=M<\_P]GXO#6N=E]">: </EPIOKB(S
MFW_K08=\A@'[VF\TAVI7I7/;AK7.R^A/-$>SY<*;ZXF,\4&'?(;3>:0[4KTK
MGM0UKG9?0GFBN2_#S<*&UC:LY0VA8Q-63@W+QZ8<1X@,"KE.S6&.(H 'I E3
M &;!JGT"8$((IBH)>C.<XVTTF05BNT190 NZYLP@]G>^9V_^S6N=E]">:*#V
M?3A3.?SQ,9NW[OUG\/>0OM;NZ'<U7O13[7U9\?Y5SZ.OYX:USLOH3S0[/GPI
M@\VT5%^[A_#H?_HW=W=W04>GG_%*](Z,K>-?X'GAK7.R^A/-$>SY<*=V]HF+
M\4&'A[O;ZQ@^?MAIO-(=J/C_ "COM\\-:YV7T)YH#P^7"G<F[:(C!_\ "##O
M-X#;OG[NIWFD.U*]([[<-:YV7T)YH#P^7"F^N)C/9_.?P[_-1M_WNT/-IO-(
M=J5Z1WVX:USLOH3S0#A\N%-Y=^T3%AN_S08=_GHP:;S2':E>E<]J&M<[+Z$\
MT.SY<*=R_P!T1&"(=S#^'=PC[ C1OL]SEY]-YI#M2K?YQWZ\?[H:USLOH3S1
M7T^'DX4,U5>2AMH2-ZN1L,9')K<4N(NA*U=1LLY6(*(4@$3&,LT0$%#)BH0"
M"4ABE.<#6]Z9'&$ZH["?SCO!AN?AGCR\N<-:YV7T#FBW^SY<*=ZXB+Y.YB##
MOL_Y#;^3=N'DW[^UR<M>\TAVH^D=]N&M<[+Z$\T1[/EPIOKB8SE'D_.?P]W-
M_J&Y^?N?9U.\TAVI7I7/:AK7.R^A/-#L^7"F^N)B_%!AT?;_ ,!O:]KV>VWF
MD.U*]([[<-:YV7T)YH=GRX4WUQ,9XG\/??\ S#<GN[M-YI#M2O2.^W#6N=E]
M">:'9\N%-]<3%^*##ON?X#:;S2':E>E<]N&M<[+Z$\T.SY<*=OW>>)BP]D<0
M8=[NX.3K'[?:Y0^SR:;S2':E>E<]N&M<[+Z$\T.SY<*=R?W1,6'=WX?P[SCV
M@_,/\^3=IO-(=J5Z1WVX:USLOH3S1<D#P\/"@OXJZO'6T)'*+0=7:RD:8N)<
M1I%2>JW6GP:BIR)4DA'!!C9E^B"*Y5$BJ*D7 @+H(J$MKI$BG!9HV*K$:QS9
MA4=N/Q#@YHD.N9]=L'$.,>*+;[/EPIOKB8OQ08=#N_Y##S<F_P"S[&KF\TAV
MI5_\X[]6/]\1K7.R^A/-#L^7"F\WGB8S?O[S^'>8>8?[QMWW_O\ )IO-(=J5
MZ1WY/Y?X\4-:YV7T)YH=GRX4W?\ LB8SQ08=\AO:[O*.[M<K>:0[4KTCOM^7
M\#-K7.R^A/-$.SY<*=ZXF+$>W^=!AWW/\!NWVM^[W=-YI#M2MG;'=OS]GB^F
M&M<[+Z$\T1[/EPIOKB8SM?XH,.^0W_/3>:0[4KTCOMPUKG9?0GF@/#Y<*=O
M VB8OW<08=_>ZQNUR?/E!O-(=J5Z1WV_)^-C6N=E]">:(]GQX4WUQ,9['YT&
M'?(;D^_IO-(=J5Z5SVH:USLOH3S17JGP\G"B2=JK$8^VA8Q9E(V*"CWB08CQ
M F91J^E&C9PF!TJ051,3HJG*!TS@<HB!B& P (4+I$@E"E!E1(23^<=X ?\
M+^7\9-:YV7T)YHM\O#Y\*:( /GB8SE* _K/X>[8?[#?\=5"CR%A=I5_\Z[[<
M-:YV7T)YHB'#Y<*</_O$1GNX@P]S^WUC=S=VNWN[0Z;S2':CZ1WVX:USLOH3
MS0'A\N%.]<3&>)_#N_\ D. ??[7L\D[S2':E>D=]N&M<[+Z$\T.SY<*</_O$
MQGL_G/X=^QNZQ_Y^V AOTWFD.U*]([[<-:YV7T)YH=GRX4WM;1,9[N'\.^S_
M )#?9#DTWFD.U*\7Y1WV^:&M<[+Z$\T.SY<*;NW^>)C.U_B@P[]X>L;['=TW
MFD.U*]*Y[<-:YV7T)YH=GRX4[=R;1,7O_<?P]N'[%&]WM]SV=1O-(=J/I'?;
MAK7.R^A/-$Y'</;PI2\@P06VAXPR*[UJBJ7BBP\03)JKD(<H&"C@(")1'E 0
M$-_TH[PWZA5'D0"0T;@7'Y1W:!_/_'CAK7.R^A/-'--\/7PHS.:EV;?:'C$V
M[64D&R"8XBQ <2(H.EDDB"<U&$QA*0I $QA$QMPB(B/*,)I-/*4DMFY O9QW
M;;/^5E_[BYVPUKG9?0GFBF!P^?"F[A'SQ,7N#_-!A[DYO\A?;^>_56\]/L3J
MS8'MCOF^'MSV_1#6N=E]">:(=GTX4SUQ,7XG\/>0P;]W)[.[?W-1O33NUGTC
MOM^3Z?D:USLOH3S1$.'SX4P=_P#=$QG)RC^=!A[FW>S1@[?S[6IWHIQV-GTK
MFSA_E0UKG9?0GFAV?3A2_7$QGB?P]Y#?/NZC>BG=K5Z1WA\>+\6/R-:YV7T)
MYH=GSX4T=P!M$Q>\?\T&'>[R\]&#M!_PTWHIYM9LW/QCORY8\OE/GAK7.R^A
M/-$>SY<*;ZXF+\4&'?(?VM5;S2':E>D=V?/^GZ(:USLOH3S1 >'SX4X-P^>(
MC!Y>4.*##OD/V_O^P(@&F\TAVI7I'?;\GXV-:YV7T)YH]EO _P"T7ES:KV#L
M79KSC94;=D>R3V2&,Q.H0L)7TW3:OWV?A(I,(NO1\9%("VC6+9N)D&:9UA3%
M58RBISG-S%09;EYIQIH%* $$ DJMB0"<R2=IX3&2VHJ0"<R;_0HCB' (\JWT
M2[_Y1&N_]6;&?N_FTRIKHJ%_@2O\^Y_9;BP_\,?S1]9C6?9ZS3LY1=CV>+?*
M/8)CD?(LQ UG:#2G"0-9@Z9"X0I<U U^58V:=AY6!C5LZ23G&]PL%C>QC\L;
M>Z+-R$FU=,Y,[=Q4^R_A>0 <" I3.&ZBI3I"E I!"CJ@%H !'6+ !%KQ2DIZ
MW/,Y*O8"P!  )V7R)\8XLHD9Z[=7ENO%%E/">.\LN<F*/\ARN7\EX8RK.6O%
MBN-L;,:5'U_.#?&->QG;*W 3T;?ANE JM>@9J06EZZQEX"\'@Q<10(M@UC;J
MVPBR VAUM*5ZQ97B:UBG$D@H*5J40+'"48K&;[;%(-[DD@Y81;KK 96-P+9V
M&9BA8CVE8%MC3#% RID&C24$RSOF"#L[.5IT;-U5G2F&,<8)8-FK?5XZL%G9
MW#M=RT@\L3^LHQ*ZTO 1EFB @7QG2L0XEQ@XW5H0L$M-J202E17K'-<$**K!
MTMG#B)%B0<238B K( V/7*OEE:R<)MEE>YMPYW'!&0Z'EZDT1_7K%M(Y'Q#E
M3*4"KG.7JDQAB0QXTL</0U-F/,,0QKC[)L+CZ9HS67M>4Y'' X8@I>O7&3Q[
M,1DVZ7K4"VF&<9)TK;4H*2PVXVA0:"DNA9!7NALX@E2PHA+87K""D*%LR02
M(%B2%'.Q3;84JX=FVULC;;G'7WM83-*M.>[W=L<+5TU$OKB+NM6:5UC&Q Q$
M9889@]\P;-"1)4HZ'OD(Z,ZC;XUCVS.(=6QM+3%>;%K<G#J*Y\H%I92E85C2
M2E142;D&UTJ/PDFUTDW.&P.=XI5:Y(V',?\ &W#Q^.-=-9,4QLSL?76G8YSW
M"W:^G$M<KV/,^NQ(E*14'(.9Y79^RBSIS""FYROVV)AK3(W%S L*E+/ZO84(
MVSN8EZ,-(B@5HIBSB5K9*$?"4IH;"0$Z]HK) *2I(0%%0"DW2#F(J20%7.RR
MO[)MMOPV R.?!&_26U'L[Y6PC>JG9*E"TJUY1E\ER,?%OIBA.X*/3H]7V:CQ
M;Z\.$<<U9^CE_*490,C#3<K0$I2JREE6RSR$O120-LE'\)@;G>;=2M"BI+00
M"0%A5UJ?!P]>H%MO&C$V0I6K LO$D"*L22"#87O:^&PL$YG(9FQSN!<[+$Q/
M<8N+T+Q:)#)>4MF2X8)>Y*Q@]V8JA0*O6(Z:Q^S;9XQY-DE%8-A4HJSXJJM=
MPJPNL!DN(R,^(I;I9^U.X9729*C<HR"AS D-H?2[JUA]2U$A9U*Q;$5$.*4[
M@4V47P#A2,C.5P24D7! 386ZX7RL"!AOMVFU[[8MI6Y4YYYI5[:!S!L_6_(E
MQD\TUG%]RKQZM:4<>TZ\;.N<Z-'CD[(^/JZ\C$ZY*Y4L^(752BWDA89>@*P-
MIM*K.J1KM1><K"5@A3+;R4)U2EMG$G&M#[*OR:%FY4&TNA1  7=*;J(PB+C8
M2DGK@#M%BE0S(RVE)&VUCF+WBT:L^QY0J=7,;5/*& &&TG7,-N$X/),HM7['
MCN#L4WG2W6>P5&%R5)PTE1(_)[G'#RLK1.0G"ZM=@XH+%3HZX1ED?MRI5.8U
MK4XIM[4*6+H%PL@-) 44 A1;"PH%(L2<*\)2#>,AE=.("P4;VS.P'9?QY@[-
MMHL!GM$9%H]$VG:C*Y@H,K;'A,;N*R_HD?2E8.6FI2<B"WY:I.XJK1<>]?#!
M=,9VR4AVXMI9\WDY0DA+=5GF'M6H0MR7.K6$]>%8RNX%C@"@I1(!4;I!V V(
M&P,1&+,<>5MMQLRXKWX.'BCKO -P ', ?S?O?/V];,;!PQ1$=(0TA#2$-(0T
MA#2$-(0TA .8/G^]I"&D(:0B \P^T//R=KW-0K8?(?JA&Z&+8&OW*C9\I3NR
MXWK-PGL=8 6I;G)%MJ]':.58=W47]@0B;#:GD>P0>A#],46;)/4EW;8JB92J
MD*)=8+I4DRZ@E92E;^,(25G/$!<)\?&,L[YYQ4 +$7 R3:_%\N?X'!&ZLO=<
M!^:.S1:;G<H#BXPAB'%%KDXF)REAW,3>QY2J.!*!7(^N0VS5$UF@VV.63S2?
MJK(C*]94FX^U0$5=98KR-0=I)EQ$H=(?2A"L;KCB02VXW9"G5FZGE*6D_D\D
M%+:2E12,SG%9(ZVYR %[%))(2!\$ $'%QFQS.RT4N1L=';1V2Y'91SC@NA1&
M2<S4[+!H_*BN.:F:"HUCHTR:W42;QW;>O@SJ$IF0AEXOK A0NBSZL%KSE!&=
M1E6AG$A*R6TS#3SA;;4T2C&JZDK 2H+3AL5(L<9PV5<96AEGA(%S?.P-K&XX
M=AV#Z3'61GF3QW,YKRM+8D9HL,92-^L[RC-&D>XB&"5;7E7*D:,9#O!,\AHE
M5$06B8=X8SN*C5&L>Z,9=LH8=G+AP,MATDKP)Q$G$;X1>YSN;[3PFYX8MFUS
M;9?+R?C\<,8F^?S^?<]V]$0'F'=S]K2$-(0TA&T6SQ+U.!S1L[3%Z=0[*I,"
M/%IUW/E0/#H,^N2]$Z-^5R11 4>G'2#<J0Q>C$F\-8+H46)D(Q%1PA.'X5\*
M>+9Y_)G$IVC_ (?O_'%G&V<K?MF*\+V21=.Z'1K]C/9#A*; 2$7%()5/.2\E
MLKUNM*QCQ-@Q5:1^>:#DZ1D&AI]WU(UNM?9K-'KIA<Z6T5O-@(F$A(&-;:YD
MK()NIK\NHG.^;2V[&UKI4<@4K.&JZ3Q A-O$JZ;9_P"4#LX"-HN,[GVI+?C&
MVS.T(WRMF;%=FH-KS.9]LRGPM"T')V2,;TT+O+R#B:+ULOJ@A#4$^.C!6G.,
M[7?X5](VB3JTXSA"&J,D]+3+H=3J2TTXE:6QKPZ5-H6K  $G$%$JU@OC0D@)
M"@3UP!E5L[J!%^ML+D"_R< V$^,<,=2$DG'HR,@C$NW3^*2?.THQ^^8I1;U[
M'IN%",GCR,1?RB,<Z<M@27<,4I.13:+'.W(_>%3!PIMDXB!B "K9@&X!X;&P
MN.(V'D$6XDM3"'S^?V-(0TA#2$72C_>/(^Q;87E_[EG@W>Z(^QS:M?XT>17U
M)_'-"+6U=A#2$0#Y_P#'M>Y]CV$(B/+\_G][2$-(1#M^X/\ -\_^>D(CI"+R
MK'Z@Y+_V'8?_ )+QUJT[_(_G_P#^%Q(V*\G[Q%FZNQ$-(0^?L?/YAV](0TA#
MY]W2$-(0TA%TT3^_FE;^;KPK&_W\8:MN_FU_S3"+4)^A+_T2_O!JY"/KY_BT
MA#2$-(0^?S_>[ND(#\]V[^?2$-(1/Q/ZJQG)O_MBR]S^R4N7W-0K8?(?JA'8
M[C3:(QEB'9HN]/E*K%WF_P!\SMFN)7@Y"9K+:&B*I8<94BLPELNU<DZ#9)VU
M,Z_.NYNP8\"#N%"/7;S7QFE'DH4AF0:MQE;CR5!10A#39Q!*KE25J44H4%I"
M218+NE=TFUA>*PH!-K DD^:PV@@Y<5B#>-K,W9KV><G9,R;=<,VS$U)R&U2S
M+C?$-GRP%#F0C;1&;0$?;(^U1MD:T&#IK"DW+"<E)5_ =PLE766QFY86.HS5
MO1>KTB[*66F7FVT(=2ZILZIQU#>-)*2R4X;8U**DN]<\D*LOK5!%PI,5$@FX
M(!S N!89WO>U@"#E>]K'/83BX;ZW4J]GCJ!FG9TAMI=2G890R=DAG(XWHE'M
M\G'W;.3VQ-HV<L4/#4^Y6*+ILSBJ-O\ /5>/7:7"3C@<)N;.Y:R$]*U8+J3C
M:>+&)W BRUK2"AH)NE)*D@J#F!*CUH/P4D@!<=DD*L,Q8 FZB>#,VM<@;1P[
M8H5C6V?,H2%!;U3)& J@KBS:,;7O+\Q(M"XYJ5QA9K$^SA%7ZY8LK9JO&+3E
M,7RCC++,I$XY@()I--65GB%:_0V,;-JQ\56G7-ZPE#JM8P4-@=>4$./J0EPA
M1PK#:V[K*B#8@J*DDF,C873DK/@!!" ;7VYA1\FP19N1<ALYVBISFSSD[ V/
M<:*56VR>0\<VN+I$5E&1R,I8[7+NG3Z'GZG,V6\2TXV<0 8NF:B[DXBA-O,9
M@FZI$C!S$F$H00JS[;JUA0P.)*BW@PI S"@A 3GK H76;W"L20(OEUI &=P;
M!7">(D\%L\O+&$-JW.TQEJ#P'%K7-C9FT5ABJO[>UCV<,V%ODX\S<6\VXF31
MD>S5//##J1";OIYS_P!CF:#N#<40R)5@-J>5A*3K%!-RHW;(3;#<D8;BXMD3
M$*)-A>^0)V;<^*--M9L4Q >8?:TA'Z)7T/O_ .2XPA_M3F'_ /*=J^?:UQ-6
M_P .=_FM_P"[3&6S^;'E5_:/U;/DM'G$^B70W\(C70[NS+C/^6F5/O:WM#_P
M)7^?<_LMQ:?^&/YH^LQI9!;'-5R=7VE#J-0L%&R5&8SV7KDUR[:K2[0Q?=+5
MM#J8L<.:#-Q\G!BC#2\1 Y36ML.[J\PN\+!8TN+5Y5YIPL$G%7=U*:5C4I*T
M%Q]LMI2,:4LXP%)(5GUS92K$+76DA0 L:,-\@,[)-[Y'$ ?)L(.1V W!X+>K
MNPXA::8I&5:SUFYY#F;G-5FD3E>M1)"NVF7>U7"%BQ[1X=&$:3\3*VZQRESO
M%'<-4IUK',K1&G.2>?1T,(R4JF\*P2DI2$I6I)00I*0IX+402DA*0A"MER,L
MBJ&'+;<W(!!!N>ML+?*?E\D658]B![5@8K2>=<,N&:L!;;=)*P,R]L#Z/J58
MK%\L+6QHP<4U7GWT79%:$M$0KX(QJQ.\ME*%9XD$E,DK]Q,Y?8RN]T)%TA(*
MEJ0G#B)"0I..Y!-[)5ED+L'^4.'9GE8D&VVQM;9Q<<8#R]A"9PVRQZ\GIJ*?
MFR=4(7(E6:,6[U)RO0;+7:_-5ZSN =(IIHMY21E)ZM)M2G5<I2U*GCJE!BK%
MNW]YIX.J4D(M@44+)L>O25!0R-\@ K,;%CAO:DBUO'G;Q6!!^L6VBT85W>Y[
M7M??]T.YR:R; ;!:(A[?_+Y_S[M(1G'9OQK#9<S%6:+8$;"_C'L7=YL\!4%6
MC>XW-W2Z%9;K&X_I[E\QE&K:UY"DZ^TI-=<'B)E1"7GF:K:#G'9$(=[CS3A;
M:4H80;I 4L72@*6E)6K,=:@**U9C))S&T2D7-LSD38;38$@#;F2 !Y8V;PA@
M>A9MS$P<6'"EIPWAZETVSW3)4;-9;BZBG:FD-)-JY 0U0O\ FAM5*_ V"7N%
M@K%<DDI*>D4QZ.5E(YDS.V"'UC.O+9:(#B77%J2A!#5R#FHJ4VUB)2$!2AD#
M\$7/PHJ !.8P@ DW-KVX 56%[Y'.+GD=ARM1M<<8M5FW*NT\3:(S#1J"+268
MN\>9SHN.ZMA">AX.EKMRJIH7&]0F3E+YBV53E%HB^12B53:%/99BHI2-&ZE%
M07A_(!EMQ8L0MI3BG02H&W6(+>!P6N@]=:P5846%K]=B4!Q$ )(^4WRX]FV,
MFWS9+P?$96A,'Q&*KR2-M$5M$RS[.;.Y3JJ>+6V--H#:*QW!66V1KZ->U![0
M:C5,45R1OJ:X0TV_8JS#R.GX^268(GMIF'2WK2XBZ3+C5%*;KUC3*E)2H=>%
M*4X0C: 0 01LD)!RM;X5U9V&%2AX^ "]\^'BBRGFSIB"L5S%XM,#Y'S/+Y0O
M5*J3IE2[E88VW0[:;V7MEG*CP:DDQA+!"'G']PS+;G##KD@)F.39M(Z.%KU.
MU77&X'G"IS\JAI*$*5UZ$D'\N^W91-B $MI!PJ!S)S)L6$ )ZTDFPR)[!!RR
MS.9X(GKWL04G#V&+#D8ZE?S+9,;WRP6VP0S++-3C$;9LX2%RG<24^>+C^LV0
MV6(.0).,:5EM*RMV!JO-8ZRO7EB2@MXEP=["9I3CH0+M!:$I2=6HX7PE+BAC
M4DMD6*VK$W"VU$@&UF  7^%:_"!=-[#*]]O7#(BQVQ6[1L_[,K*X[9<<WI4#
M3HK9[RU4\24P+G<,_P!B9SH2J^<CO)1X.+JK=["-K?)4" 38D?Q\/1VJ3:3,
M^?-';YFFM"7I@B6)65%YM;BB$L@C"6<DZPI2$C&J^95F+"UR!">ORMA-A?%;
M^5GD#ML,CEXXZBB[^A+OY^A#?O[N[V.3G[G)W-;8;!Y/)%N(\N_M>WV_GRCR
M;^3NCOTA >0!'N (_>T.P_OV?+".SJR["M)=0<$RQS<+7*95>7B23XNI@D2J
MM<\9P&-<(72W26/WK".;*N[]3U\F3,R]JCIHX&;HT<O)PQC2=6D6$_K$SKER
M5I2&\ Z\7ZU96ZE.,7("5X  K8E9 .2@17A!&1-[VMM)&%)RV9Y[-AV W!CG
ML.R=L^L+K0,%L>.DN3\I0N9)6N9'5N-+D,?5USC_ #7GC&U>;6S':.,XZP&K
MJD)AYI*7:XL\F-0KJ,K+V)"N.H^%"%=R)I\I6Z=46T%L*;PJ"CC:96K"O&1B
MQ.$)!00;!)-S<3A&0SN;V-\LE$9BU]@X#\G!&.+E@7 N%ZA7[YDM#-%XBKVO
M2X.LP]"L=/IQJ[*.=GW!>8[I+V>TS]"NK*4,I)YI0C:;26$##/%8>#>OI>WE
M4Z29S6)AYQ:D(U2"C$5%:5*Q /.MI"4A:;"S?7J*CF>M3Q4V  )!S RN 0<*
M22<CE=660RX8J-3V-$0V4?/66JJY<G8.-M;FT25>KZD748R4V>F5C)B]U/QU
M\DJG=V,5D0F5WK=N>$6K\T@E2(J=LIF!F2!'J<*FSNC<Z5-I44A()!60\1K+
M% 4DE&K!SQ#KR!MR,A'6XB#8'Q $;,CGF#XMD9 FMCS!MOR];<5XM6RY30I>
M2,-T9_,76VU+)SV;9Y%K=YMDT]@H"N8TQ<H>>:L*HWB*I6S2;@9Z?=)-UI-J
M5^B1G;3-O);2XLM+Q(=79*%-V+:D( 42MRR257*K9 7X"(8039-Q8@&]CQWR
M '%EQQ:>)MGG9?SF"-NKZ^T#C''54MU@J.1T;/*47(=B?M2X(SGF2 M%&EXJ
MF8^ARR4:.$G[*WX]E8M\HFUGH,\;>"B^478W%S$RUUJM2XM20ILA*T '6LMJ
M"P5*)2=;="P1FD@HRS ).?7 7L;D'@)RR&RV8MPC/.,%9SV:G.$,:8_M\C+>
M;SJ_9+RE"5JS0JH.*!><8U>G85LU'R!2EG$<TDU4+"KD>?;RJ4BJ1Y#O8@*S
M+P\%9H*PL0NLS)><4BP3A0V5 @XTK4IT+0K.V0;%B,C?$"4D1!38 G:2H>*P
M"2"//_[1JK\^[_S]O67%,0'?R]W<.[V/=Y/8]WM\FH5L/D/U0C</$^-JK;&&
M7K[9*7:<IJXEQ7B>:C<8U&6<0CF4ZXV=4KKRX6=_'1TK/!0:21=$)YO7T&,D
MXF+!6$E9R&BS2+H<%UQ2=4@+0C&MP:Q0! PW5@ *@G&K^3B!%DJR48J2+W)%
M[ 9"XO>POPFW[R."-O8_9HV0ZICUYEK-4?:L6P=DC<&2ZF.K58KX_P AX['(
MR&T\C+UNGC4Z"\0FK):&F%JCD?&0Y>C*O7D:/;FC.QV!V==C9)?&+TRI8;;*
M5E)=&-*4!*\&HLI14K)*=:I#@;*E8TE0'!%82C,JNGX.1)N+XMF7#AN+Y6VD
MQA66QK@2S5G#!Z_B16FRF1]EK: SW+RC3(-PFA9S^+9/:=JT#!L&4T[=-2PS
MAUB&JST@9<JK]1TI),DG24>Z*@E=#CH4[=S$$3#3(!;0FZ7 PHDV S <4 0>
M(CCBDX;"PM=).TFUBH?N$;21FQGL13V>,[XRJ=CRC//J7EZLU-G1Y!<T6?%D
M!%[4]!P%<8^PVT&!$L@25W;6I].T9_"IL4JK7&[8EG+)V=X9.*L*F9I+32R$
M)Q-J45BQUBM0MY)2D? "2G"H'-1)PV3MJP)Q$7)L0+;+#&$G/AO?+Q;<XU.#
M!=8LN(L*5J+P8XK>?]H2PTEMCN4);;RXB8C&SE\,"ZRG?$)EXK7(@F1[(!PJ
M<?N9H1-1@[)<GZ2<)-T5Z^R"\M+CI4[C99"RL!* 2L"X;1A&(E(&9SN2E&T+
MM3;(##91V9\''Q"_CX,]EKYVR=LP[/&'K)DATRQ^EE7&*F!YW,&+;'QV,YUV
MWFZ%<ZIB^UTRS3N&[)+TITZ?2;M;)'F8R?FFH"MWNF1S]8BI%05M-S#[@1=P
MH<UH;<3JK#"M*G$J2'4A0  #>RQ4A1SL(DI OE?*_P *^RP-[9<9\AMMV8NL
M.S]B:BT.'R<PPQD'-*EM<83A%:+6;A-Q\;C=2];-N&LP/Y6;?PD#/61]*Y)L
M^1K+!XK1=F:0S!+'EL!XRM[HB3.,K#SJEELNH:PAWKU)3=80^ZT$@$I39M*$
MEP[>O18IVF+"P(!5<#+,6.!*K\>=S;Q#AX+^L6PQA]W8:EBVARMT)F>1R_:6
M[.EVN5BEG5WQ_"J8]5L>)VZL6Q;-(S/^*T;#.MI%JW,G%9"=0=FB8)A$VR+K
M5<ME")MT!;BPG5I;22M(4 A9QA+N9-V7+#-6: 1<E)4H3@3D!>Y)VVV997'\
MH>8Y\-A&NN,,.T6[;76)<)V5-R./'E[M]0?I&?RB#D*_$9$R0B@5>1AV;V9#
MH$(] 7:\8P=22I 5%FU6<G32->6XI,JXZG\X$MJS"2,9;3?(Y$9Y D#C-HI2
M 5 '9?Z/-^[Y(RK.;+V$;OC_ *5CB581>9KAF>\T[#[>!D<AIXJR SH&*,!6
M=]C1OQV5BE9#A;]9YC*<RYILY/QK"(E;!#FHZ+9RVLM7GF- ?=0KKQ=H-I4Y
MB",;96X\G6$-*4@I2&P%!-U!)"K9*$24@C+:5$#;8V"3E>QSOE<#BXC%]Y7X
M/FJ5JC;6,K7EW#"[T++6;7>$*C*Y!I",_)83V>;LM4;F+BA2LNTR);WUA:K7
MJ:C+1 P+J-A3;.-XC9(!6LJ"K&A$VI2I>XNA;;0=.!0 =>1B3UX&!(2<"5)*
MDDZ])'P,Y*  KC!-LQL2;'(F_&;V_DF\7;M";#N#JS&Y,D\714X_'&\9GF#?
MEA9F_/&3:U457$CK'[&1;7RG5N3EKB:-L5_<7@]$<6G&0MDJF,)-HO#O"O(8
MFWB6]:H=>6CF$7*5:T*L4*(PW",..RP<5Q:)4A()M?A'#M ! S SVW N +9W
MC E<V8\&/\!U*Q7.;G,>9$R!2L7HUFWS,H"%%KV3;?F[;JJ1TLA1KEBHYCJ;
M/5W9PI54<2;-=JI2YR14NDAU9"H348XO&9=#RP@!:$+=*D =<6TM2BNL-P"I
M*GUJL?A"Z191!BFPL. D @^,J<!OXK)&?'QYVOJP[&E3Q8**%@Q);[Y>7-DP
M)C"R4B1O#^FUW#MHNNS?B')]HL.1YZ%AIF3;J7R\7JTP.->C<Q]:BDJ+;#.T
M[45%BT:VQ-*<N0Z$)"'EA> *+J4ON-I" HBX2A"2YUI62I-L.9B2D#:"?@BQ
M-K$I"C?AX3;B -XZV,E5%[0,D9"H<C&*PLA2;Q;*B^AEYAI85XEY6YY_#.8M
M:?8,XYC.+1ZS([16791T>TDCHB];,FJ2Q$$]BRK&VA8-PI*57 *;@I!!L22,
MCD"3897)SBV=IBRM781E?'%?:VU2LU5^JY;,;-EV@5UZNS,D5TBSFAD(URLU
M,NDNB5RF@X.HW,J@LD"A2BHD<F\HXSBB@J4-J4.*'#F$@[.*^W98</# "Y \
M?XM&].7]CK9_;L<I*X<R[&QDOC"QTBLSL=DG+U1G:U$/[#:,V0[AJ]R'&XUQ
MY#RD_*0F/:Q/,ZS$Q1QK'FA,L92:G'0$2B<9J<?NWK6R4N)6H%MI060$MJ!U
M>-9"05E.(GKA8@)X;A2,[$9<9O;;P@ 7RV#9XXJJG!N2,G7=IB;J2EZLG%9'
MUMMBM[!,65CK5OLL+B2OYMS(2R3\='-T&4/$4N3(UH:S5)HM8['9:K%I*/S%
MD1-&[[*8"L"<9470KK5!)<+392DG-6(76+Y *-@ (8#UV1RV6S%P+FYMQ;-E
MS:.&B[)&SG9J^C?B2=[FL;16 7UWD[@?-V-L?PD_EN#MVS]5+?2'TC.8<L;W
M#;RE/,QOTY&HVNO7->P-TZ5.U6]2D)93.4"YN82K!9"5EX("0TM92V4O*"A9
MU(<"PV % I .(*0",P2DY\&&_P (#.Z01\'*U^(WX#&DE,QQ6+BYVA%TW,FR
MC<88XLM[J232:C)SJI6-R31JE&LI>=1A(]G/,?,>U.EEI2)BH ))XW:OFK:/
M:'.P-EJ=4D,?!)=<2VHD$"Q0M1(3<E)ND6!*K7SOMBBVWQ;,[\(&WAVQ@OY_
M/F'61$1#M]L/<_G[ON]WDYATA#M[OL_S?/W>3D 4(O.L?J#DS_8=AN\9>.O8
M_'_-JT[_ "/Y_P#_ (7$C8KR?O$=G.2-B+9M9HY"KE!RV[A\E8WQ<\NTO$7C
M)]1F*ZF)+'L_PT98+9.1V,:@PQZUEE<G76);8_<R=HL99&"@Y!Q8FS-SU)*Z
M]N=?N@N-@MK<"04-J"K%+I*4C&HK(#:25V2FQ(L;7%90,['8+FY'&BQR&7PB
M+;;B]^ R^,.#7)DNZMZM$6>=FXX=G*AW=2S40&%W@'&;,NV"PU3&\"G+1L:D
MU8XT(_AW=AM\^Z*LXAZO6+0<)$'AF'05.5 MH*BE(.O6@)7UAU382I9L2;N$
M&R0"+DIRM>(""=@)R!RSS.S9P7\N0BS\);)&%LBPN-EYAUD%>48HY=)M%G3R
M-2<?)XTN%$QIG?(%<QS*5ZT8RL$Y249YCBJ#?M\L/%[[4I%JYND(M!UVRUHK
M%:79MY!78( _)ZG\FI>-*W&D%84' E5BM5V[)4.L5<I5>)2D$"]^&^8%K)4;
M'(D7MMS&W*XC N,L:86N6TVMBZ3BLBO\?3<NC"5U2@94H%BD:\@9:,7G+I8\
MG/L;QU2G:?2*NE:;=.N6=(K"*[.((T=2U>9(R$^A>6\\F7UH+84G-6-M8Q9&
MR V%E04I6%(ZXYG*Y($4V&*V=M@L0?E)M:PVG(6&VV9C5%^BT;OW[=@]\TF+
M=ZZ092(-U&G5[1)<Z;9[U(L)EFO52)2+]3+&,JCTSI9Q$Q1'64DE202+'A&V
MQXHIB3^__-_PY-50B/+\^[_/][2$731/[^:2(\P7"L?QXQWCVQYO9YAW;M6W
M?S2_YIA&\.$=F[9\N.SS4,A9+NMEJMZOV4L@X]JXL+O7$&KAS36^%582&C,8
MK8XF[):7MH=9,E(^3M)+_6H.E(M8Z7?1DP1):-D,-Z8?0\4-I"D):;62I!/P
M];<J<Q@)PAL$)P$K-P+;16$I(N202HCZN"V9SX\LLHJT3L!K66=D*E5,@UBV
MV)WM4X^P;!ITFUP]U\P*3887.-@MUKO$9$,$7C:5K<+BUI,))-56R*S-G:$@
MCW"Z;06D&>*4A2VR@;G6Z<:2G$L*:2E*"38I47+7SS*3LO>=6;V!!ZX)L#?(
MXC<^3#XN'Q1/V_8QHE'OV>L?RC;*ZUL;4:!RILRT"=EZQCV]6G&UCIULNLA*
M6E&;J$M"W"\8N3BHFMW;&%<?T69L<G'WQU1Y9^YKC:!?PF<<4AI8U6$K4V\L
M!2T!84E("2% I2X25)<4%@ H"@+XH%(!4#>]@4C(&Q!.>1S&5QD=MMEHPWM;
MX?PS@V\UNG492PRB;!<Z5Z<N\R4F]3;TJ3.NNSE2K4!BJG*8ND#@^DR-XVQ2
M-[,L;I(=4%\RW0R-V7?>=2I2PD7'6IU2D &Y LHN*U@.5RD"WU0H $6^7,'B
MX@+?3%C;46**7B:\5)ICQY,NZA>L48_R;$DFK+!W9:/&X1JRTA#MKQ7*[3X>
MWH0\FS>1KF59U2O=22S:3@'$>=U"KOGEV6=6ZA16!B0XMLD)*+X3D2@J44D@
M@V).1!&VPA0 .6PB^V_T@"^8XA&M@^WN^_SCW-WW^UO'61%,1^?SY TA$_$[
M_-:,Y>3S18\G-_ZTEOY>3V.WW=0KX*O(?JA'9#AC9SPUDO .9KS:Q57RLG;=
MH%ACR&C9ZR,[=87N-<3P^08=A28)O /Z/.BREY->4OT?;)R!FWE!;2G%Z67M
MK-I&+ZQUYU#K24_FR&L9*4E("UE)*E$XTDC)!2",93C*4W,5(L4J)V@J  O<
MV (L+$',YC;:]N"*W&;*&.F3"@NX;%UGR]+94MF.* BU5R*[HU,QC(3VSM@G
M*"J]DL<=7IMRWM&2K3E*PHT)2>.VJT5'5)^W"(N"YGB=?@S"R5@N);#:%KR:
M"U. //(&!*L(P(" %X>N4I0S3M54$C+(FY .=@.M!S/ 22?%D; \$NRV-,-H
M.L;)V/)U8KUFE-F3:0R79,+R"^4I&^S5[Q,AM1D@UX*U5_%[K%Z,*DYQ+6C.
MT)"\0AY%&%GC@T:FEH]NZ;I>.,!M2DA]E =&KPA#A8O=*G LDZU1%DJ(*AGD
M3$81E<V.%9MG<X<6=[8<K#ASL8I,71]EN;D=FYO)X:D:DRRWAVY9*G)>.NN5
M;/#Q-EC;_F_%]6CK*WB&5GLL7C(\O2*C,6Z;KL-)6F/Z:^!@/4*QVY9*Y@!\
MAT+U;B4 %MI*BD(:<5:^%)792@E*CA-AE>T39)PY$7%SF3L*ALL<LA<C/RVM
M&AV5:7(8ZRAD>@2T$K69.DWNVU-_7'$VSLSB =5^?D(I:&7L<>U9,+ K&*-#
M,U)QDR9-98R OF[-JDN1%//9(6TVNX5C0E>+"4WQ"][&Y3MV$DC9<[8H(L2+
M6L2+;;6X,LO-%A;@#V/F/_/5V(@&_EY.;D  [8;@^?<TA >;M>SOY YOQ^S[
MO=0C]$KZ'W_\EQA#_:G,/_Y2M.N)JW^'._S6_P#=IC+9_-CRJ_M*_P#:.AWZ
M(LPQ=;SM\5J>@4XLT>;9QQVR 7DAU,MT]K<\G&5#I72%/I-RQ.A-T7+R\G)K
MT[0/06O:2T5VH4Q,H9=$^_*J+\SJEZUMF6<5UI0KK<+R+&^9N.".(TET[H6C
ME213JD9P3*I5J:&HEM:WJG7'FTW5K$V5B:7<6R%C?/+I;FZ+M3V5A5(NQY,M
M-@C*'U"%&CIO)]FEF-,"+10;Q@5-F_<N&]<".0;-D6 0Z;/J1%N@DWZ6FBF4
MO8)Z#VE*<6%BE@KOB(FT JOMQ$,@JSSL;@G,WCGST6M$\KKJ9ML&XB;6V6_*
MD#Q1*26-MIF8>FDI?($]*R*DTULIW\CD:P/GI[$Q,<S&?.Z=+*KGFV9CG,TE
M3*"_;F4.*3@@F-O#H/:5 6#-, L183:+6.1'YG8>$;#Q0ZK6B9SQ5/;?_ C>
M_'^>^GQ>2\D;$NT2:N,J>-QD1J<:C)H1M7&^3(UV/0F5BN9=!E"";S,:HRKD
MA'$DF@U(1^L4BKH%5"E, ]!_2LG$&:9CRZ[=B;FUP+D,WN!>WEAU6M$[6Q52
MW%N(_5KK1,7O$69\ASB$Y--*DS%A7JM5(B*B9-VC$PU=IM=C:Q Q<:@\%^Y(
MDA&Q:!W*SAVX=/Y)9[*/G#A\^=+J2WT(=+6DD!%.S4I1)GA<E1*B20R!M)X
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M/4G%<JOJ$!5R;WN#MX;WXR<XJU;MK8LN+$>#8.*,9MOH>_A4&4.K7F;G&;.
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MXV[+I4PM@I(U;B7,32D("5%>).&R<P$F/F9,RTRU)%M+K,PB:"T*:==;FFG
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MXT)%P$H5AND $@!) %S;;%76FX9P"97#627!)9)PD"U9G50370."B*Z8'BC
M19$X =)0NXZ9P Q# ( .K*2M-\*BFZ2DX5@72H64DV.:5#(@Y$9&+I2E5@H
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MA N\1"=WB/0E*7?S[B@', :CI'T+'_1/1P?[%IWC_P"K^6'37I1X1UWE:?\
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MD&% @ZQU)N^XFYEV>NNEUU@GV6M6K=DU;,FB1$&K1!%JV03 0(BW;IE212(
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M]+3_ .@7^"&OS+5M/E/UQ][)V#R#ZH^]1$PTA#2$-(0TA#2$-(0TA$# (E$
M$2B(" &+NZ(HB&[>'1 8N\.<-X"&_G 0Y-(1TSR.UUM1X\DI.;L,0_NE'V3Y
MEY@[:09-*8T1LV9\EY$>3;/#%SI98UBW28. CS[/%FGHZN-T*RA';1ME(\31
M-CY%-EL1+L+  (2I](=9)4<+:$8=8E5]N>N2"23=D=EG;*E \82;'+,WO8\-
MN [+9[<B(O2H[>V18J+B*#-4.)M-]JN1*KAZ\Y(O-Q#&E5F+"RODCB_(]J<L
MX_'CY"M-CW"*!Y38V,1GXES5I^&>S,]%SB1ZV]I5*H)*TK*4*2IQ"$HQJ *
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M2E<K*3<X\EPE!#4DTIY\ 6)U@2A02@@75D2-L=%,SK$JW+NN%2D3,S*RK1;
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M)_MR?;%_'I"'3$_VY/MB_CTA$>C)^W+]L'X](1#IB?[<GVQ?QZ0CB<*$%!<
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M[WJ'9D=K+U.8$\6#CRGTZA.A';:[RDW[I#JOZ7=A1O47?>_+^#D[,CM9>IS
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M>RD>$DGR?5_<X;Y5?P=F>4:9[Q#C R?WA+1X<8S\J?G^\WLI'A)*<GU;W/\
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M9&I^-7>);^>W5F1SMYHRI8^EREJ=U^%19TJ<KD<_LQ;X,4FE7DZK;HB7C59
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MH]SN\V[>/;#E$-_<Y.7F$=XZ#,\7'LM<\(S(OQ99[";F$-_+N_%W-W= ?=
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M4JY4;#:;Y"VV-G)4^3IZ%HE60V758WG5*6[,3#EK:R9F'5+??<L D+=<64I
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MW+[,\X^R#</8W\H^SOY0T_A+:9=Y]'1Y&:AQW[OOG;.'\*[HE=RZ-<G3/O\
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MX;MIG>9OUZ<]N'61E/OVR'@!2_BNF-OM(^>OGANVF=YF_7ISVX=9&4^_;(>
M%+^*Z8V^TCYZ^>&[:9WF;]>G/;AUD93[]LAX 4OXKIC;[2/GKYX;MIG>9OUZ
M<]N'61E/OVR'@!2_BNF-OM(^>OGANVF=YF_7ISVX=9&4^_;(> %+^*Z8V^TC
MYZ^>&[:9WF;]>G/;CX)1,H$,J8N;9'>LH"A]]!I8_3 DFD&[^Q.0.@2)R=W>
M/;TQM]I&7^6OGANVF=YF_7ISVX^^LC*??MD/ "E_%=,;?:1\]?/#=M,[S-^O
M3GMPZR,I]^V0\ *7\5TQM]I'SU\\-VTSO,WZ].>W#K(RGW[9#P I?Q73&WVD
M?/7SPW;3.\S?KTY[<.LC*??MD/ "E_%=,;?:1\]?/#=M,[S-^O3GMPZR,I]^
MV0\ *7\5TQM]I'SU\\-VTSO,WZ].>W#K(RGW[9#P I?Q73&WVD?/7SPW;3.\
MS?KTY[<.LC*??MD/ "E_%=,;?:1\]?/#=M,[S-^O3GMQ+C2LG]5D(.:9 5!;
M*F*MUATT!*0%40,GT'4O0"!S&*;HA#H@$@  [C& 6-KM(^>OGB-V4VX.\[=K
M'+=TYF<K&^.^5CY;^(1,=9&4^_;(> %+^*Z8V^TCYZ^>)W;3.\S?KTY[<.LC
M*??MD/ "E_%=,;?:1\]?/#=M,[S-^O3GMPZR,I]^V0\ *7\5TQM]I'SU\\-V
MTSO,WZ].>W#K(RGW[9#P I?Q73&WVD?/7SPW;3.\S?KTY[<.LC*??MD/ "E_
M%=,;?:1\]?/#=M,[S-^O3GMPZR,I]^V0\ *7\5TQM]I'SU\\-VTSO,WZ].>W
M#K(RGW[9#P I?Q73&WVD?/7SPW;3.\S?KTY[<<2E"R>J=!0^;9'HFRIEDMU"
MI8!T9D%FX]$'4GTP=*<*<G)]-T([^3<+&WVD?/7SPW;3.\S?KTY[<<O61E/O
MVR'@!2_BNF-OM(^>OGANVF=YF_7ISVX=9&4^_;(> %+^*Z8V^TCYZ^>&[:9W
MF;]>G/;AUD93[]LAX 4OXKIC;[2/GKYX;MIG>9OUZ<]N'61E/OVR'@!2_BNF
M-OM(^>OGANVF=YF_7ISVX=9&4^_;(> %+^*Z8V^TCYZ^>&[:9WF;]>G/;AUD
M93[]LAX 4OXKIC;[2/GKYX;MIG>9OUZ<]N'61E/OVR'@!2_BNF-OM(^>OGAN
MVF=YF_7ISVXXUJ'E!=)5%3-LCT"R9TC[J#3 'H%"B0VX>I.0=PCN'M#H%M@@
MZD9?Y:^>&[:9WF;]>G/;CDZR,I]^V0\ *7\5TQM]I'SU\\-VTSO,WZ].>W#K
M(RGW[9#P I?Q73&WVD?/7SPW;3.\S?KTY[<.LC*??MD/ "E_%=,;?:1\]?/#
M=M,[S-^O3GMPZR,I]^V0\ *7\5TQM]I'SU\\-VTSO,WZ].>W#K(RGW[9#P I
M?Q73&WVD?/7SPW;3.\S?KTY[<.LC*??MD/ "E_%=,;?:1\]?/#=M,[S-^O3G
MMPZR,I]^V0\ *7\5TQM]I'SU\\-VTSO,WZ].>W'R>C91.4Q#9MD>A.4Q1W4&
ME@.XP" \O4G<'3&WVD?/7SPW;3.\S?KTY[<"47**9")ES;(]"F0I"[Z#3!'H
M2@!0WCU)RCN .73&WVD?/7SPW;3.\S?KTY[<?761E/OVR'@!2_BNF-OM(^>O
MGANVF=YF_7ISVX=9&4^_;(> %+^*Z8V^TCYZ^>&[:9WF;]>G/;AUD93[]LAX
M 4OXKIC;[2/GKYX;MIG>9OUZ<]N'61E/OVR'@!2_BNF-OM(^>OGANVF=YF_7
MISVX=9&4^_;(> %+^*Z8V^TCYZ^>&[:9WF;]>G/;AUD93[]LAX 4OXKIC;[2
M/GKYX;MIG>9OUZ<]N'61E/OVR'@!2_BNF-OM(^>OGANVF=YF_7ISVXR+7F$O
M&1:#.<GE;+(IG6,M+K1S&*4<$45.=$@LHTB;1/I"0E1 R90%0"=,/].8=4**
M2;I3@%AE<G/A-SGG&OF'&772MA@2S9  :#CCH20+$XW"5G$<[$V%[#*.@OA3
M?V1D#R?XJ:YW.3\T=PY=X\WS]@=?)'1Q_3&6_H*2_:ZA'D6F_P#&[/\ H#/^
M_F8U[:X/9+X#6N1BM0OJB#J_LD36B%3>*X[C7GF$ZBRTT\B6?5D5Q"1O 3!8
MLS!*JP:ARNNB<="'(HT:0K18U"S>^BDN55M)GI4.FD,.;E6R*:7MV*>6==4]
MT!G4ID)51QG&+:A--2JE*F>MW40J:0G7MXC)MKU*D;FQZTK)"YG6ZO &&KX^
MNM'PPQ[3&P5^;=0GFFWC]G)?*TI7UI"51;VBRDNLM6").W#)\VDV48@V492L
MDUA'D<J>/@WA&Z[)1TL]3K:I%.0B2G%RVO2SHBNN/R:GGD)GYQ%5F)%(<4VM
M+R&$-EM^81+N,J+,LX$+:*U."E,K+@M.*:QH11S/N-EQP)?>$R[+A*E)6EQ"
M DH<6&5-DH:5A*%*4N*=?\<56ML\PK1K-V0];GL3#7TWCYPLYA&-\KT[8)2"
M>"4R*+YU&*$9Q*CETW%R"D:<X @JNX*;'J='D91K2-3+;@,E,T)4F''%*<E6
MZG+S$R_*N$84N+9."74M:,6)DJLE14(IFY-EE,\I"5#4O2&J"E**FDS3#SSC
M*\PE2FRE#94I.(%LV*<2@=< 'E^SO#?NWAW/<[6_E[0#OW:X^-3$ Y^UR^[N
M 1Y^72$3#3ZJ:B')N<(^WRJ%]@-X#R]W=N'5;7YUO^>C^T(E.T>4?7'K1S=:
MIREXOEK#6UU&LRA)4J.:N$(U*8<I)S]UKE?>F9Q:^]%\]Z@E'(,FR@"51V*(
M" \VOO32:H3-+HC\Y)J*9A#],90I+*7UA,W4Y*4=U;*NM<<U+[@:2<BYACW>
MJ/NRTDX\P2ET.2R$J#8=4 ]-,LK*6SDM6!Q6$'^5:+$Q->LG2E\?5*_I=3LT
MJ>^L,$=_"LX&P2T>G<74/'S,S%M'S]&+>KL"ID7CDE4B%)U*]691KAZ=@WUM
M!JM:F*J[(55&K;$B_-RNMEVY:;?83452[$Q,LMNNI9<4U8*:24BP;<4VTMPM
M)Q9":G5S:I:; "1+*>:*FDM/.($PIM+KC:5K#:BFP* 1EA4I#:EEM/#@[*MM
MOCY1"?<,5T.*RLVY(6K))MT4G+7C)\&LN!DQ'HFRT75X;I*0?UL#D67((BX-
MNMZ-5VH5284W-K:4D4*1J U;003,3%3K4LM5P;%!9D9<)2!8$*4"<<44JH3$
MVHAXH(W"Q,#"@)NMR:GFB;@V*2VPU8#+(J!ZZ,85#.>=92LX4?3]4BV#>RS.
M/G%IO"***D/;H&^HIK1,54XLKH74984"K.D[2=XGU-&+0Z!HLCEO96BD9I:;
MI1I1,2.C3TW(,-(G9BE+GJFA*3+3\K5$8V&*>P%EQF;0"L3NLZQE3"2R%HG&
M]3AL5.J+9IJG&$)2\[*%^:L"W,LS9 :;ET W;>LH[HQ );4V, *'TEN]HW)6
M3>+NFYR>6&LNZ_;GU+<+8U;5X4SL(&]3\7",8J+LY94\B[N\*$RU._.Z9*14
MK),7\2WAHCIZ+YILVZU6=YJ?I,N:DG)6?=IZU4=N6L6Y6IS3$LU+L3NN+KE2
MEMT(+I<;++[[;K"9=@*2MO)1.SIE):J*>8+,RJ5)D@S8H:FW6VD-H?UA6J::
MUJ<94@MNK0IM+36(+3;KG:#NT'6+H-H1BXZ4=7*[L,465!I_:F=CZMDV4JCR
MJ2B"QS)(W*)B8MQ)IIE$B,[!'\T6)#O(B<(A@N:7U*5D:B9U+#+ZZC4F:%.)
M;.YIIJ1K;U/<D'TJ-DU%B794^E(LF:EB76@7)>92FP:Q,ML36O"$+,S.(I[X
M3^3>1+SSLN9=8.0FFVVBX$C\\R=8CKFG@FZI;(.3CTC(.8XVSU.-@J-*WXC3
M'TA7S*)OX?',Y+0LDSL%G&53D8^SV 8-XXC5F+-..A#2,8V=1$X*"ZSS8NU>
ML+IE6TA9G))F5IDS54MTIV5Q:V7H\U,RKS<U.%X/-3LV99;C);;2U+EQA"V)
MFRU.9#LW/;EG*DV_+H9E%3F&36R2'&Y)UQM:7G]8%MOO:I1;*$!#6- 4V]8E
M59',%B9XXRM<3-F"\A6LB/:E7$)1(S*/CVSZ1K,/$.+$+4Q5Q8PSF?&0G5DU
M$G!H]HY*19$Y2JDNG2.<:H]?J2FVE.R-973I-#R5----NNR$O+KG,!Q:N67.
M%V:4"E1:;< *+ BZ*B\F3GY@A!6Q.+EV0X,"$!2V&VR]8@X6U/8W2"DE"3F#
MUT2=NR%D###I-6V34=DZ.DZ3D*R(L8NMIUB>CI>@UQ2SK U(TDI)NZJ\HW1/
M$AU6W4DXF5=1(*RDJ1^*2$SU6JFCSB=W3+-9:?IM5FTH:E!)3+,Q2I-4XO"&
MW7D*DGTI+'Y1)>EWE,XGGPX0FB8G)NF*!F'43R%RLX^$-L!AY#DFR7SA"7'$
MF7<2-4,0*VG5- N.ZRR9YK-9%,Z;5I;+=:7O]MI+FTUJ,;XRE"4Y-VU49.2&
MB;*5^Z;/H-(!,PEF#Z4>6-Q'R"$NQ4B3]3 I6B:JV-J2779-=6GZ:N=DV4T9
M\4X.(*%@R\Z'%H<EDB[3[3C[LXMEQ$PWJ"4DUI<G<08546%3<Q+*?80F1<$N
M%)*#=M[&H+9&:'$+6I]2%AQ!;.$&\<*W"VY&K:]^L39E!QM@='1K-3:'3?+P
MC&&6<14BYEIDJ:?FE)2TRV?N$R-R(LF4.E%(E1%^:165S]&JE/5F1-6FVVY5
MF;64R4@V0ZN7:EU*8>7,3  USS\RAU20A*6VY<,)L72ZHY%,F9B<95-O)2TV
M\HAB720LM(:);6IQRPQN..A9 2 A+0; &/&HYDUT<;*&D(:0AI"&D(:0AI"&
MD(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0B3-^J"7UFO\ AV^D
M(G-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(
M0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$>?#A3>3:-@!_S4US^4=P[FODKHX_IC
M+?T%)?M=0CRC3?\ C=G_ $!G_?S,:J)4;)"L!2<B1DV]?6&R)25=91J:AFSV
M&J$16G<+'.7TH[<(,&L+(5N"M# S1QU,T85R#,\=K&CY%("<,FEUA<K2ZJQ,
MNNSL^'Y-II)P.,2$O)JE65./.*2TB7=DY:>:*%X6VI.6UCJM4Z+:'<TWJ9>;
M0ZI3CR5M! .%34LVRMI*ENJ4$):6RR^C"K"E##)4I6K6+0BJCM ,)BOR<2WL
M<=/5YG(5ZNJI33!A*Q[!C8)6LO85@W5D4774SBR/9: 1CRHG3F)-ZXBV:3U5
MV#=29>G:6M/RC\NB<9F9)MZ4DR)AEI]EMN9?E')9E"G4N%"YMR8EDM)21,/.
M+9;#JEX50VS5$.M*;2\AYI*F62'$H<0E+SDNIM QA=B^IQD)M^4<4IM 6I0!
MH;^I9B>)V<TDWFGP3*+&Z6WJJ89/',DX,SFYU@^E@/(J.W<^,<6P3)(M?H[
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M38GFS((F4OKFD* ?U;<TZ"')IJ6(,NU,N JQS#;27EW45+)4J]I*:,A[7I#
M=QEP'K\*758BIU+7YM+JKJ*G4H#BKJNHW,5.1FMGJ6KJM4E'-:?UU:<7LIXM
MTC(+(!/N+ O:EI9(YTA60>C8'"\F"J*J8IKJG(F!$1%+5]Z<T/F)14@\[(NR
MBYE4XIA:75(W4N;5/%\73B2X9M:G@I)!"E$"R3ABM:Z2XR9=986RIU3Y;5B(
MUJWC,%S,7"B\HKN"+$V%AE%+D/.S2U@5LT@6K.IAP_:2SPYTY0&,C+L.D]03
M$I#$*6&E)=D+=L+25D8]S(-A;-A1<D%NB)+#R]"7IM4\\9!<PMYN8<4H/AIZ
M8: #4P]+@"6?F&PE.!]UI;J<""%C FU"TT9;Q?<#!<*TK43CP+<1; XMK)IQ
MQ-AA<6A2TV%E"PM]D5V<23$W.B]BU7ED-*'GV[F1LSJ$F#333J&5-(UMRX5K
MKKJ]I_67'38LP'* #R& #!(=T+$Q,S&NEE.3BGU3:%/3CDM,JF6RT^7I-:U2
MCI=;)2O&P;C/: 8#><..NXVRI\K+J5..J;<+J<#F)E2BR<:<E?D\Q'/5GVSE
M2G;I]6W%>8/WC L2J]6-+R3PD.50%20C5S*]6KL80BH%4)#,E&\80Y2'*T Q
M2B%<B_H;35K=DG9-I;C(EU.*,P^L2Z3<2R'']:IJ6! (EVU)8! (;!%XJ8-(
MEE*6R64J4C5E9*UJ#8-]4E2\10T" 0TDAL$"R<A'!65-FNFRJ<U63UV(D&S5
MVR8';FF#M8=B_.DH]904<X%:.@&;H[=$7#6&:,&ZO24P.F)2  6Y)S0FGS"9
MJ27),/(;<99*%3!1+M.J2IUJ5965,RK;A2DK1+-M)5A2"+ "*6=YY=P.L%AM
M8"D((*REM*R"M#*"2AI*B$E26DH!L+C(1>$#D/#=8B6L' V"'C(ED+CJ1D@$
M@9)$73I=XXZ$545%!%5TX76-T1S?3*& -Q=P!L92LZ-2,NW*RD[*L2[6,MM(
MUI2@+6IU9&)*CURUJ4;DYJXK1D,S5/8;2TRZTAM&(I0"JPQ**U',$YJ43MX>
M**QQPXS]5\;W/T+SG[GU-K(Z9*%WRE^/_&;./X$7-WR?=#?'M.SCV0XX<9^J
M^,^U=_%M3TR4/ODQ_6>Q#=\GW0W]/-$..+&?JOC/M7?Q;3IDH??)C^L]B)W?
M)]O1]/-#CBQF'/;XP/\ LN_BVG3)0SLJ3!])[$-WR9V3"#Y^:(\<.,_5?&_:
MO/BVHZ9*'WRE\]GYS/\ \$1N^3[H;\YYHAQQ8S]5\9]J[^+:GIDH??%C^L]B
M)W?)]O1]/-$>.'&?JOC/M7?=W?\ PW=Y/;U'3)0^^4O_ %G%?L.+/R1&[Y/N
MAOZ>*_%Q9^2''#C/FZ[XW?W.A>?%M.F2A;=\I>W'^4]B&[Y/;NANW'<\T0#,
M>,C!O+<(P0WB&\"NQ#>4>A$.1MS@;D$.<!Y!Y=3TR4/ODQ_6>Q#=\GW0W]/C
M\7B/F,1XX<9ASV^,#_LN_BVHZ9*&=E2ESZ3V(;ODSLF&SY^:''#C3U7QOVCS
MXMITR4+OE+_UGL0WPDNZ&_.>:''#C/U7QGVKOXMITR4/OE+_ -9[$-WR?=#?
MT\T..'&?JOC/M7?Q;3IDH??*7_K/8AN^3[H;^GFAQPXS]5\;]J\^+:=,E"[Y
M2_\ 6>Q#=\GW0WYSS1#CBQGZKXS[5W[7_P -W>34],E#[Y,?UGE[#BSB=WR?
M="/I\O%Q9PXXL9^J^,Y.?Z5WR?\ ^-ITR4/ODQGL_.9_^"&[Y/NA&>S;G]$
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MI"&D(:0B2DOU.?\ UDZ_ *:E.T>4?7")W40AI"&D(:0AI"&D(:0CA<?4Z_\
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M%-YHI,\4L$EMM#$NC"W*2C,O*I"M27%[B8>*<(0I&%L61^4:2$A.PI 4 G8
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M;PHM$UC CU*@A]G="IO2!O1*4373UE[TE#H5NM%,*$EA,P5'X-\6Y4D!:)?
M%'#@2CV/105!-):W=\$F\F%WUPE2!@#ES\&]RT#UR6BD&PP@;R:]*CI8:0AI
M"&D(:0AI"&D(ISWZIA_]8J_Q3*:0BHZ0AI"&D(:0AI"&D(:0B2DOU.?_ %DZ
M_ *:E.T>4?7")W40AI"&D(:0AI"&D(:0CA<?4Z_^A5_@&TA'RT^I6WUNC^#+
MI"-%^$W@\F6383VAH3$!;6>_2%;KR482D#*#93Q1+U55K<5@E#"$FZ1-3DY\
MLHQ: H=_$B^9'172<'14ZW01V18TMHSM15+HE$/O%:IO5ZA+FY)@2REZW\F"
M)DLEM2LDN8% @@$<YI<B:<T<JJ)-M]Z84RV$M2V/7.(W0SKD)U9"R%,ZP+"=
MK96""+@^(1I3J-.1$%&XTBY%3-,E*DA&+BNRMEDK2$_''0,U58P3-^Y/YJO'
M8-"D;-(LBS=8CTK%%JNW0.E]8EY]MV9?FIA IJ62M:W@PF7#:TD$.NJ0EO5H
M3<DJ4 4E&(D*S^9KE+<E)B269H3 ")5*' _C;4,V4I.M+JU* 3:Y*L>TI,>E
MC:.AN$+*ELC/7E7EIJCU3'L-65*M"Y GRVFS9%D=D7)!<CW#.)6])FWJ,K%6
M@H15..>7=QR<ZU70=]7SU\8/:UX!17-$+Z1)$PVW-OSCKX?<E&=SL22-()+<
M<O2B9EM"FW&3K)BS:5EI22G U*K0][W5-_<=(6&'%RK;*$!I+RDN.OJI<P7W
M)P:M:TK0KK6\9PA:%)(+CR5(LRDU9^[QSL_H[-E)S_5Y%CL],8S;7<R=9S/3
MZC.6@]3H[:'9H161&,='V;*[3*B;V2)8,=Q[M9E64[3YL2BD0_8H'VTK,-LU
MN>579JBNM&L.NZ-I+]+F7FF,<ZI96[*+46)!4E@;+4XM(4^9<--AU*B.!Z),
MJ_-=#NKM:.R]:$XY2Y1F?$BU4FW5O;NIH(99PAU<VAS6.!Z5;)2R'E+4ILY=
MI2N&+TKF;&$3EFWS65*F^K>2X(B'4\C'0S"NULE1>5%U:%HTS=->\S+Q5=Q-
M3!UVZ<HM&M462 )-7 *<B*[3A0:L_1I&7H\ZW-TB9*\;;LP[-3>[T3R)-+H4
M4TYA"4HEY=*5%E+RU.K*EHMK5:":1JT\T1DM-*[4=,:-,4C2ZG);#,U*TZ7I
M=+W@?HC]9<E2TVYI'//J<<GY\N,HG5RK3<LR$,NXLD[(>/X^L8V1GG4#(15N
MDYN]1LHXECS!)%>)C[]8D8-%5K*+FZ6W3BV[#J-4B!!6:%05!15-0#FU>FM3
M=FZJJ61,M/R+,O3764LA@M)>=IDJJ94E;*1=1?6[K$XB$N%22$D6'4=!#1N7
MI.B:*C,4Z:DZW-5+2>4FW9Y4\F;<D);2JKMTQM;,XX2EI,@U*;G6&TER7#2P
MI:%!1VSUQD>TPTA'GOX4W]D9 ?N4US^4=P_Y:^2NCC^F,M_04E^UU"/*--_X
MW9_T!G_?S,=;':Y^;E_& =KV?:]T->.1QT;45?*]1LM>A*K="O*W+P<.PKT7
M86D@Y+7).,BDQ)&-9]J2/FG<*Z2 QBFE&,?+,W;E1)1RSADTW3]2]4)"D:0I
MEE3Y>DZC*RK,FU,)F5HD9F7EDX6&GTB5G')-P JQO-2\PV^XI)<1*I#KRNAE
MJHTY+M2LP5,J:0EI#B5J##B&_P VE](0XI!2;_E$H<2202EOKG(C**-*\A+(
M/F]F9OVK%"QT\S5E#VAHX>2#^/JX2$#.QTO'LIY)1679/V;F*3$J4M!QZ?3%
M1371-F4>AMTX.M/RT^R\PA,[3@42L\WKGELR)?E)R7>99G$*#S;Z%L(PIF)1
MA-U8519?4EH.!8>2M*0]+X4-/I45*0R%M.H=0ET$N)6A38 #K2!F04QB!W2*
M9#J%=9$0L31TF)1)1V5BCC6A_O)T91G2-H,S6@H'$1 4)"3E[,R5 A5JLLU6
M*_+T3;5%HB0J>;F'9M  33FYELOWPWO.*0QJY!)-R6UN3$XA>''*E!+AUJY2
M72<4X'DD;)5+R->L$9!T)9*90#L5../)( ,OA(7%LV^RN;A8Y2QO&S9DM)K)
MG*S9].%JS;MD$F;-HB9PJJN<C=HW01Z:LJJLJ)!55.90YM<Q4IYRISTS/.H;
M;7,N8RVT"&FTA(0VV@*4I6%MM*4 J4I1";J45$F+;[RIAY;R@E)6;X4WPI
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$/CC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g162874g92m89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g162874g92m89.jpg
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M 0$! 0$! 0'_P  1" !8 2(# 1$  A$! Q$!_\0 'P !  (" P$! 0$
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M12SR2.P5$11N69F(55 ))( KXDD2)'EE=8XXU9Y)'8*B(@+,[,=@JJH)))
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M>UO7XK37_1Z[WSRQ_P#?UI\8B_I5IWT/9[[393XC<_BZ?8=RS][2]?BM-?\
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MG4BKPNRS.LIN%Z332[6)ZI(6N%P+E7'5I>+J"LZ>2N.X*RU1K)/5S")UW\S
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MS_'62/ZC3-6+\'O]&:H_8V*_E;ZO-CYHM]:>%/OCJ[Y-IZH;=M(@&XW  C[
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MSD0[BI+RSOQ95ZDB95JQCZ1<0-=7FM<J9?7+?$6;.F,L2?8H3LUU<!25:[G
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M:OT74TI32E>6]B.E#58#SKY$4YJ:*FX=E4+PJS:@ BU8B @!B'*4PK.B"!3
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M !T '0"J36O0ROSEU<$Z?_R.,"_@BY^L,UJB7$WV^:E_9X^305[Y>"U_V?\
MAC[PR_A7(5N)K1*GZFE*:4JJ_P!6'Y85B_ FB_V2;5S>"?M$M??')?RPKQ/\
M.3]/W*?M;TU\B>N^]&_Y4-R^@ZT?7C'&L9Q[]I^/_;%:?@[*ULWS/W].C4'^
M37-?SETA5F/51:]BJ:4J#7K7_M=V\_QUDC^HTS5B_![_ $9JC]C8K^5OJ\V/
MFBWUIX4^^.KODVGJACV[CQN P8//'&8L9#S[..+K">O/S<:G[5?M7U)[P9C\
M'7->>W"<[<4^&A[MN(&C3O\ <U'C:NS:\]J_1A32E-*5#5O_ .BWMVWF!-9
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2TI32E-*4TI32E-*4TI32E?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
